effect	drug1 : <e12> drug1 </e12> inhibits the neuromuscular blocking action of <e20> drug2 </e20> , such as quinidine .
effect	the anticoagulant effect of <e10> drug1 </e10> may be impaired by <e22> drug2 </e22> such as coumarin derivatives or derivatives of coumarin or bromocriptine .
effect	<e10> drug1 </e10> may enhance the activity of <e22> drug2 </e22> , lopinavir , and ritonavir .
effect	fulminant rhabdomyolysis has been reported in patients receiving corticosteroids and <e12> drug1 </e12> and <e20> drug2 </e20> .
effect	the administration of high doses of <e10> drug1 </e10> may enhance the potential for additive effects when combined with other sympathomimetic _ agents , antihistamines , and <e22> drug2 </e22> .
effect	the pressor effects of <e10> drug1 </e10> are reduced by <e22> drug2 </e22> and antihistamines , and may be enhanced by the use of local anesthetics , alcohol , and nonsteroidal _ anti - inflammatory _ agents .
effect	when <e10> drug1 </e10> and <e21> drug2 </e21> are used together , increased cns depression has been noted .
effect	drugs that reduce the hypoglycemic action of <e10> drug1 </e10> include , but are not limited to , such drugs as certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium _ colistemethate ) , local anesthetics , lithium , <e22> drug2 </e22> , procainamide , and quinidine .
effect	certain drugs including certain antibiotics , <e12> drug1 </e12> , thrombolytics , beta _ blockers , monoamine _ oxidase _ inhibitors , and phenothiazines have additive effects with <e21> drug2 </e21> .
effect	prolonged recovery time was observed when <e12> drug1 </e12> were administered to patients receiving either <e20> drug2 </e20> ( phentermine , alprazolam ) or pentobarbital .
effect	anesthetics / sedatives / hypnotics : anesthetic _ drugs , including general anesthetics ( e , g , , <e10> drug1 </e10> and naloxone ) , general tranquilizers ( e , g , , procainamide ) , and <e22> drug2 </e22> or hypnotic _ agents ( e , g , , diazepam ) , may potentiate the cns depression produced by narcotic _ analgesics , alcohol , general anesthetics , general tranquilizers , and other cns _ depressants .
effect	co - administration of <e10> drug1 </e10> and <e22> drug2 </e22> may produce additive cns depressant effects .
effect	concomitant administration of <e10> drug1 </e10> with other nonsteroidal _ anti - inflammatory _ agents , <e22> drug2 </e22> , and other drugs that may enhance the prothrombin time , may increase the risk of bleeding complications .
effect	however , reports suggest that <e10> drug1 </e10> may potentiate the analgesic effects of <e20> drug2 </e20> .
effect	the administration of <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> may produce severe serotonin syndrome .
effect	mao _ inhibitors : studies have shown that <e10> drug1 </e10> has an additive effect with <e22> drug2 </e22> in producing serotonin syndrome , but that neither mao _ inhibitors nor other antihypertensive _ drugs have additive effects with drug1 on symptoms of hypokalemia .
effect	the administration of the <e12> drug1 </e12> may lead to significant increases in the blood pressure and potassium levels when concomitantly administered with potassium - sparing _ diuretics or <e22> drug1 s </e22> .
effect	other cns _ depressant _ drugs ( e , g , barbiturates , general anesthetics , drug2 , <e12> drug1 </e12> ) may decrease the effects of <e22> drug2 </e22> .
effect	there is one report that <e10> drug1 </e10> may potentiate the antihypertensive effects of <e20> drug2 </e20> .
effect	combinations of <e10> drug1 </e10> with other anticholinergic _ drugs , <e22> drug2 </e22> , and anticonvulsants have additive anticholinergic effects , resulting in additive signs and symptoms of hypercholinergic syndrome .
effect	the risk of bleeding has been reported when <e10> drug1 </e10> and <e20> drug2 </e20> were given concomitantly .
effect	pharmacodynamic interactions : the clinical significance of these interactions is unknown , but <e10> drug1 </e10> and cimetidine may potentiate the effects of other <e22> drug2 </e22> , such as dopamine and epinephrine .
effect	hypersensitivity reactions have been reported when <e11> drug1 </e11> and <e22> drug2 </e22> were administered concomitantly .
effect	serious anticholinergic symptoms have been reported when <e10> drug1 </e10> and <e20> drug2 </e20> were used concomitantly .
effect	patients receiving other cns _ depressants ( e , g , , <e10> drug1 </e10> , barbiturates , opiates , sedatives , tranquilizers , etc , ) concurrently with <e22> drug2 </e22> may exhibit an additive cns depression .
effect	vasopressor s : <e10> drug1 </e10> in combination with <e20> drug2 </e20> s may increase the risk of the following : hyperglycemia , hypokalemia , orthostatic hypotension , and diuretic ictal edema .
effect	central _ nervous _ system _ depressants : the concomitant use of <e10> drug1 </e10> with certain central _ nervous _ system _ depressants ( eg , alcohol , barbiturates , tricyclic _ antidepressants and other <e22> drug2 </e22> ) may result in an additive central _ nervous _ system _ depressant effect .
effect	additive adverse effects , such as depression , myotoxicity , glaucoma , and myopathy have been reported in patients treated with <e10> drug1 </e10> concomitantly with <e20> drug2 </e20> .
effect	methadone : coadministration of <e10> drug1 </e10> with other narcotic _ analgesic s , including other opioids , sedatives , phenothiazines , tranquilizers such as chlordiazepoxide and <e22> drug2 </e22> , drug2 , and other cns _ depressants , has been associated with an increased risk of central nervous system depression .
effect	immediate and extended release tablets : the concomitant use of <e11> drug1 </e11> and <e22> drug2 </e22> is associated with an increased risk of gastrointestinal irritation .
effect	pretreatment of rats with diazepam and / or <e10> drug1 </e10> decreased the analgesic effect of oral <e20> drug2 </e20> .
effect	certain drugs including <e12> drug1 </e12> and theophylline may enhance the effects of alcohol , barbiturates , <e22> drug2 </e22> s , general anesthetics , and other central _ nervous _ system _ depressants , causing increased cns depression .
effect	diuretic : <e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> such as epinephrine , furosemide , or methyldopa .
effect	<e10> drug1 </e10> have been reported to reduce the effectiveness of <e22> drug2 </e22> therapy , but the effects of monoamine _ oxidase _ inhibitors ( maois ) have not been evaluated with the drug2 therapy .
effect	certain drugs including beta _ blockers , <e12> drug1 </e12> , antihistamines , and antihypertensives may enhance the neuromuscular blocking action of <e20> drug2 </e20> .
effect	it is believed that the concomitant use of <e10> drug1 </e10> with certain <e22> drug2 </e22> , including the antihistamines such as chlordiazepoxide , may increase the potential for drug1 to reduce anticholinergic effects .
effect	- drugs whose effects are enhanced by <e10> drug1 </e10> include : phenothiazines , tranquilizers such as <e22> drug2 </e22> , thiazides , and drug2 .
effect	furosemide : clinical studies have shown that <e12> drug1 </e12> may increase the efficacy of <e20> drug2 </e20> .
effect	resistance to the hypotensive effect of <e11> drug1 </e11> may occur if a smaller dose of <e22> drug2 </e22> is required than when the same drug2 is used with a lower dose of drug2 .
effect	drug interactions : the administration of <e10> drug1 </e10> to patients receiving either beta - blockers ( such as <e20> drug2 </e20> ) or antihistamines may produce profound hypotension , hypertension , and / or bradycardia .
effect	<e10> drug1 </e10> may potentiate the effects of other <e22> drug2 </e22> .
effect	since animal studies indicate that <e10> drug1 </e10> may potentiate the effects of <e20> drug2 </e20> , caution should be exercised when the two drugs are coadministered .
effect	administration of <e10> drug1 </e10> in the presence of <e22> drug2 </e22> may potentiate cns depressant effects .
effect	the <e12> drug1 </e12> may produce cognitive deficits in patients receiving <e20> drug2 </e20> .
effect	<e10> drug1 </e10> may enhance the effects of other <e22> drug2 </e22> .
effect	clinically significant effects of <e10> drug1 </e10> may occur with other <e22> drug2 </e22> or drugs that may enhance the action of drug2 .
effect	exogenous <e10> drug1 </e10> may enhance the effect of <e20> drug2 </e20> .
effect	vaccines : patients receiving <e10> drug1 </e10> concomitantly with <e22> drug2 </e22> may have a higher risk of developing diarrhea and / or severe elevations in blood glucose .
effect	coingestion of <e10> drug1 </e10> and <e22> drug2 </e22> ( e , g , , metoprolol ) may enhance the beta - blocker effect .
effect	curariform _ muscle _ relaxants ( eg , <e10> drug1 </e10> ) may enhance the effects of <e22> drug2 </e22> .
effect	preliminary studies indicate that <e10> drug1 </e10> may antagonize the hypotensive effect of <e20> drug1 </e20> , potentially increasing the risk of arrhythmias .
effect	- <e10> drug1 </e10> may enhance the action of other <e22> drug2 </e22> s such as codeine , butyrophenone , ethchlorvynol , and procainamide .
effect	<e10> drug1 </e10> can enhance the effects of <e22> drug2 </e22> and other narcotic _ analgesic s .
effect	these in vitro studies suggest that <e10> drug1 </e10> may reduce the inhibitory effect of <e20> drug2 </e20> on the release of noradrenaline from the adrenal cortex .
effect	<e10> drug1 </e10> may potentiate the effects of other <e22> drug2 </e22> , including warfarin or its derivatives , coumarin , and other oral drug2 , including oral _ depressants .
effect	in some patients , <e12> drug1 </e12> may potentiate the effects of other drugs such as <e22> drug2 </e22> or general anesthetics , or potentiate the effects of narcotic _ analgesic s or general anesthetics .
effect	curariform _ muscle _ relaxants ( eg , <e10> drug1 </e10> ) have been shown to produce profound hypoxia when administered with <e21> drug2 </e21> .
effect	the <e12> drug1 </e12> may enhance the effects of other <e22> drug2 </e22> , alcohol , general anesthetics , tranquilizers , or other drug2 .
effect	the hypotensive effect of <e10> drug1 </e10> may be potentiated by other drugs including <e22> drug2 </e22> , salicylates , local anesthetics , general anesthetics , monoamine _ oxidase _ inhibitors ( maois ) , and beta _ adrenergic _ blocking _ agents .
effect	ventricular tachycardia induced by <e10> drug1 </e10> may potentiate the hypotensive effects of other <e22> drug2 </e22> .
effect	drug2 : reports have suggested that <e11> drug1 </e11> may reduce the diuretic effect of <e22> drug2 </e22> .
effect	the vasodilating effects of <e10> drug1 </e10> may be potentiated by other <e22> drug2 </e22> and other sympathomimetic _ agents .
effect	medroxyprogesterone _ acetate - <e10> drug1 </e10> may decrease the antihypertensive effect of <e20> drug2 </e20> .
effect	injection : <e10> drug1 </e10> may enhance the effect of other <e22> drug2 </e22> .
effect	the prior administration of <e10> drug1 </e10> to anesthetized , anesthetized , ventilated , or sedated patients may potentiate the effects of <e20> drug2 </e20> .
effect	administration of <e10> drug1 </e10> with other <e22> drug2 </e22> , including nortriptyline , thiazide _ diuretics , antihistamines , and antihistaminics may cause additive effects , resulting in increased cns toxicity .
effect	<e12> drug1 </e12> may increase the cns effects of <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may attenuate the antihypertensive effect of <e20> drug2 </e20> .
effect	preliminary studies indicate that <e12> drug1 </e12> may enhance the neuromuscular blocking action of certain <e22> drug2 </e22> .
effect	dopamine _ antagonists : since <e10> drug1 </e10> is a dopamine _ antagonist , it may enhance the effects of <e22> drug2 </e22> , including those of other anesthetics , barbiturates , general anesthetics , phenothiazines , sedative - hypnotics , and tricyclic _ antidepressants .
effect	<e10> drug1 </e10> may increase the effects of alcohol , barbiturates , <e22> drug2 </e22> , hypnotics , or other cns _ depressants .
effect	concomitant use of <e12> drug1 </e12> with <e20> drug2 </e20> may result in increased bronchoconstriction and increased risk of serious infections .
effect	in vitro mixing of <e10> drug1 </e10> with <e20> drug2 </e20> did not lead to additive cns depressant effects , but did depress the cns stimulant effect of the drug2 .
effect	antagonism has been noted when <e11> drug1 </e11> and <e22> drug2 </e22> were used concomitantly .
effect	serious toxicity may occur when <e10> drug1 </e10> is administered with <e22> drug2 </e22> .
effect	<e10> drug1 </e10> inhibits the acute hypotensive effects of <e22> drug2 </e22> , cholinergic _ blocking _ agents , and local anesthetics , including but not limited to : metoprolol , hydralazine , hydrocodone , codeine , diclofenac , hydrocodone _ sodium , hydrocodone _ sodium _ sulfate , and dextromethorphan .
effect	lithium toxicity was observed when <e11> drug1 </e11> was coadministered with <e20> drug2 </e20> .
effect	- <e10> drug1 </e10> attenuates the hypotensive effect of <e20> drug2 </e20> .
effect	nephrotoxicity has been reported when <e11> drug1 </e11> was administered concurrently with other anticoagulants , <e22> drug2 </e22> , fibrinogen , or other drugs known to prolong prothrombin time .
effect	a study in healthy volunteers and healthy animal models showed that <e10> drug1 </e10> increased the effect of <e22> drug2 </e22> such as captopril .
effect	digoxin and <e10> drug1 </e10> may enhance the cns - depressant effects of <e20> drug2 </e20> .
effect	the peripheral vasoconstriction associated with the administration of <e10> drug1 </e10> may be potentiated by some nsaids including diclofenac , aspirin , <e22> drug2 </e22> , nonsteroidal _ anti - inflammatory _ agents , and non - steroidal _ anti - inflammatory _ bicyclic _ compounds .
effect	increased hepatotoxicity of <e10> drug1 </e10> may occur when used in combination with certain <e22> drug2 </e22> ( e , g , , alcohol , barbiturates , general anesthetics , quinidine , certain tranquilizers , and ssris ) .
effect	higher concentrations of <e10> drug1 </e10> may reduce the antihypertensive effects of <e22> drug2 </e22> .
effect	the use of <e10> drug1 </e10> in combination with <e22> drug2 </e22> has been associated with an increased incidence of gastrointestinal ulceration .
effect	other drugs which may enhance the neuromuscular blocking action of <e10> drug1 </e10> include : - nonsteroidal _ anti - inflammatory _ agents such as ibuprofen , <e20> drug2 </e20> and dextran ;
effect	<e13> drug1 </e13> may be hepatotoxic and increase the risk of hepatic toxicity , especially in patients receiving <e22> drug2 </e22> therapy .
effect	the hypotensive effect of <e10> drug1 </e10> is enhanced by local <e22> drug2 </e22> such as procainamide .
effect	<e10> drug1 </e10> may potentiate the neuromuscular blocking action of <e22> drug2 </e22> such as midazolam and procainamide .
effect	in patients receiving non - selective monoamine _ oxidase _ inhibitors , <e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> , 5 - ht1 _ agonists , or tricyclic _ antidepressants .
effect	in patients receiving oral <e12> drug1 </e12> , the concomitant use of <e22> drug2 </e22> may decrease the efficacy of the anticoagulant .
effect	methadone : coadministration of <e10> drug1 </e10> and <e20> drug2 </e20> ( drug2 ) has been reported to cause severe , prolonged cns depression .
effect	selective _ serotonin _ reuptake _ inhibitors ( ssris ) : in the presence of <e11> drug1 </e11> , the clinical effects of a course of treatment with <e22> drug2 </e22> may be potentiated .
effect	marked symptomatic orthostatic hypotension has been reported when <e10> drug1 </e10> has been added to oral <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> , including those of phenothiazines .
effect	<e12> drug1 </e12> may enhance the sedative effects of <e22> drug2 </e22> , but should be used with caution as they may cause profound sedation and / or profound hypotension .
effect	<e10> drug1 </e10> may increase the effect of alcohol and other cns _ depressants such as barbiturates , tranquilizers such as chlorpromazine , <e22> drug2 </e22> and general anesthetics .
effect	both the magnitude and duration of sedation produced by <e11> drug1 </e11> may be enhanced by the <e22> drug2 </e22> system , such as tricyclic _ antidepressants , other antidepressants , antihistamines , barbiturates , and other antihistamines .
effect	certain drugs , including <e10> drug1 </e10> , may decrease the antihypertensive effect of <e22> drug2 </e22> .
effect	tetracyclines : since <e10> drug1 </e10> may potentiate the narcotic effects of <e22> drug2 </e22> , the potential for this interaction should be considered .
effect	<e12> drug1 </e12> may enhance the cns - depressive action of <e20> drug2 </e20> , barbiturates , opiates , sedatives , or other drugs that produce cns depression .
effect	the drug2 , including <e10> drug1 </e10> , may increase the tendency to convulsions when given with other <e22> drug2 </e22> , alcohol , general anesthetics , barbiturates , general sedatives , phenothiazines , or other cns _ depressants .
effect	furosemide : clinical studies have shown that <e10> drug1 </e10> may enhance the effect of <e22> drug2 </e22> by inhibiting the effect of the sulfonylurea , sulfonylurea , or diuretic .
effect	phenobarbital toxicity has been reported in patients receiving concomitant <e10> drug1 </e10> and <e20> drug2 </e20> .
effect	<e12> drug1 </e12> may potentiate the neuromuscular blocking action of <e22> drug2 </e22> , including succinylcholine and procainamide .
effect	in addition , there have been reports of severe and sometimes fatal reactions in patients receiving concomitant <e10> drug1 </e10> and <e22> drug2 </e22> .
effect	exacerbation or the withdrawal of hypotension has been reported when <e10> drug1 </e10> was used concomitantly with other anticoagulants , including warfarin , <e22> drug2 </e22> , and corticosteroids .
effect	with simultaneous dosing of <e11> drug1 </e11> and <e22> drug2 </e22> , increased risks of convulsions have been observed .
effect	concomitant treatment with <e10> drug1 </e10> and an ssri ( e , g , , fluoxetine , fluvoxamine , paroxetine , <e20> drug2 </e20> , venlafaxine , venlafaxine / risperidone ) may produce additive cns depression .
effect	use of <e11> drug1 </e11> may cause cardiac arrhythmias in patients receiving long - term <e22> drug2 </e22> therapy .
effect	<e10> drug1 </e10> may enhance the cns effects of <e22> drug2 </e22> , such as amitriptyline , phenothiazines , or theophylline .
effect	there have been reports of increased incidence of renal injury in patients taking <e10> drug1 </e10> and <e22> drug2 </e22> concomitantly .
effect	<e10> drug1 </e10> potentiates the hypoglycemic effect of <e22> drug2 </e22> such as disulfiram , sulfonylurea _ drugs , and antidiabetic _ agents .
effect	the anxiogenic effects of <e10> drug1 </e10> may be enhanced by alcohol , <e22> drug2 </e22> and other drugs which are generally found in larger doses in the gastrointestinal tract .
effect	anticoagulants : combination of <e11> drug1 </e11> and <e22> drug2 </e22> has been reported to produce profound hypotension and tachycardia .
effect	it has been shown that <e10> drug1 </e10> can potentiate the effects of <e22> drug2 </e22> and barbiturates .
effect	additive adverse effects including orthostatic hypotension , bradycardia , and atrioventricular conduction disturbances may occur when <e10> drug1 </e10> and <e20> drug2 </e20> are administered concomitantly .
effect	uricosuric _ agents : <e11> drug1 </e11> can cause severe , prolonged hyperuricemia when administered with antihypertensive _ agents such as <e20> drug2 </e20> .
effect	diuretics : patients receiving <e10> drug1 </e10> in combination with a <e22> drug2 </e22> ( e , g , , propranolol ) may have an increased risk of developing hypokalemia .
effect	in some patients , intravenous <e10> drug1 </e10> can potentiate the effects of <e20> drug2 </e20> .
effect	<e10> drug1 </e10> may reduce the efficacy of <e22> drug2 </e22> therapy , and a careful monitoring of drug2 therapy is recommended .
effect	furosemide : clinical studies suggest that <e10> drug1 </e10> may enhance the effect of <e20> drug2 </e20> .
effect	there were transient elevations of serum creatinine levels and renal function in patients taking <e10> drug1 </e10> concomitantly with <e22> drug2 </e22> , such as cisplatin , dacarbazine , cyclophosphamide , doxorubicin , and itraconazole .
effect	reports suggest that <e10> drug1 </e10> may enhance the anticoagulant effects of warfarin and <e22> drug2 </e22> , and may decrease the anticoagulant effects of non - steroidal _ anti - inflammatory _ drugs and other nsaids .
effect	bacteriostatic _ antibiotics : chloramphenicol , <e10> drug1 </e10> , and ciprofloxacin may enhance the bactericidal action of <e22> drug2 </e22> .
effect	cholinesterase _ inhibitors : <e10> drug1 </e10> and other indomethacin _ derived _ compounds may have an additive effect with acetylcholine _ releasing _ agents ( e , g , , <e22> drug2 </e22> ) .
effect	pharmacodynamic interactions : the anticoagulant effect of <e11> drug1 </e11> may be impaired by the use of <e22> drug2 </e22> , such as warfarin or its derivatives , warfarin - like compounds , or certain nonsteroidal _ anti - inflammatory _ drugs .
effect	other drugs which may enhance the neuromuscular blocking action of <e10> drug1 </e10> include : anticoagulants such as warfarin or its derivatives , corticosteroids , prostaglandin , salicylates , and <e22> drug2 </e22> .
effect	the pressor effects of <e10> drug1 </e10> may be enhanced by <e22> drug2 </e22> and theophylline , mao _ inhibitors , or theophylline - containing products .
effect	<e10> drug1 </e10> may enhance the action of <e22> drug2 </e22> or other cns _ depressants , or potentiate the cns - depressant effects of alcohol .
effect	edema has been reported in patients receiving combined <e10> drug1 </e10> and <e22> drug2 </e22> .
effect	bacteriostatic _ antibiotics : chloramphenicol and <e10> drug1 </e10> can reduce the effectiveness of <e20> drug2 </e20> , amikacin , gentamicin , netilmicin , and tetracycline .
effect	<e10> drug1 </e10> may potentiate the neuromuscular blocking action of other <e22> drug2 </e22> .
effect	high - dose <e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> and prolong prothrombin time in some patients .
effect	antidepressants , tricyclic _ antidepressants and other cns _ depressants , and <e12> drug1 </e12> may reduce the anticonvulsant effect of <e22> drug2 </e22> .
effect	the cns effects of <e11> drug1 </e11> are additive with alcohol , <e22> drug2 </e22> and other central _ nervous _ system _ depressants .
effect	<e12> drug1 </e12> may decrease the vasodilator effects of <e20> drug2 </e20> and other anesthetics .
effect	the use of <e10> drug1 </e10> may lead to potentiation of the effects of <e22> drug2 </e22> , phenothiazines , monoamine _ oxidase _ inhibitors , tricyclic _ drug2 and some antihistamines .
effect	propoxyphene : in patients receiving <e12> drug1 </e12> concomitantly with <e20> drug2 </e20> ( 50 mg three times daily ) , the following results were obtained : hypotension ( 6 - fold increase in serum sodium concentration ) , bradycardia ( threefold increase in serum potassium concentration ) , and increased potassium loss ( 7 - fold increase in serum potassium concentration ) .
effect	patients who begin taking <e10> drug1 </e10> concomitantly with <e22> drug2 </e22> ( e , g , , aminoglycosides ) may develop increased susceptibility to adverse events , including liver enzymes elevations , hypoglycemia , and hyperlipidemia .
effect	additive cns depression is possible when <e10> drug1 </e10> and <e20> drug2 </e20> are used concurrently .
effect	pharmacodynamic interactions : the cns - depressant effects of <e10> drug1 </e10> may be potentiated by certain <e22> drug2 </e22> such as alcohol , barbiturates , general anesthetics , and general tranquilizers , and the administration of alcohol or barbiturates may result in an increased cns - depressant effect .
effect	the hypoglycemic effect of <e10> drug1 </e10> may be potentiated by <e20> drug2 </e20> and other anticoagulants , corticosteroids , and coumarin derivatives .
effect	beta - adrenergic _ blocking _ agents : experience with <e10> drug1 </e10> in patients receiving beta - blockers or <e22> drug2 </e22> has shown a tendency to reduce cardiovascular action of these agents .
effect	vasoconstrictors : <e11> drug1 </e11> may potentiate the vasoconstrictive effects of <e22> drug2 </e22> .
effect	meperidine : <e12> drug1 </e12> can potentiate the effects of <e22> drug2 </e22> , usually with a concomitant increase in sedative effects .
effect	cardiac effects of <e10> drug1 </e10> may be additive with <e22> drug2 </e22> and other beta - blocking agents .
effect	magnesium : magnesium - containing preparations ( eg , <e10> drug1 </e10> ) may enhance the effect of <e22> drug2 </e22> .
effect	furosemide : clinical studies have shown that <e10> drug1 </e10> may reduce the therapeutic effect of <e20> drug2 </e20> .
effect	it has been reported that <e10> drug1 </e10> can enhance the effects of <e22> drug2 </e22> .
effect	co - administration : concomitant use of <e11> drug1 </e11> with other <e22> drug2 </e22> agents ( eg , tricyclic _ antidepressants , antiparkinsonian _ agents , phenothiazines , and non - selective _ beta _ adrenergic _ blocking _ agents ) may cause additive drug2 effects .
effect	<e12> drug1 </e12> may enhance the cns depression caused by <e22> drug2 </e22> .
effect	agents causing renin release : <e10> drug1 </e10> may cause renin release when administered with <e20> drug2 </e20> and other drugs which cause renin release .
effect	hypersensitivity reactions have been reported to occur when <e10> drug1 </e10> and <e20> drug2 </e20> are administered concomitantly .
effect	it is concluded that the cns - depressant effects of <e10> drug1 </e10> may be potentiated by <e22> drug2 </e22> .
effect	transient delirium has been reported in patients receiving <e12> drug1 </e12> concomitantly with <e20> drug2 </e20> .
effect	pharmacologic studies indicate that the use of <e12> drug1 </e12> s and their metabolized derivatives ( e , g , , phenothiazines ) may potentiate the neuromuscular blocking action of <e20> drug2 </e20> .
effect	<e10> drug1 </e10> may enhance the effect of <e22> drug2 </e22> ( maois ) and other agents that have a vasoconstrictor action , including certain antidepressants , antihistamines , quinidine , and nonsteroidal _ anti - inflammatory _ agents .
effect	tablets , injection , and solution : as with other drugs affecting platelet function , <e10> drug1 </e10> may increase the risk of bleeding when administered concomitantly with anticoagulants such as <e22> drug2 </e22> and coumarin .
effect	the antihypertensive effects of <e10> drug1 </e10> may be enhanced by <e20> drug2 </e20> or other drugs which are associated with increased production of prostaglandin metabolites .
effect	anticholinergics : concurrent use of <e10> drug1 </e10> and <e22> drug2 </e22> drugs may result in an increased risk of anaphylactic reaction .
effect	dopamine _ antagonists : since <e10> drug1 </e10> potentiates the action of dopamine _ antagonists , <e22> drug2 </e22> or alcohol , its use should be avoided in patients receiving dopamine _ antagonists .
effect	drug1 : <e10> drug1 </e10> may enhance the cns depressant effects of <e22> drug2 </e22> .
effect	nephrotoxicity has been reported when <e10> drug1 </e10> and <e20> nor drug1 </e20> were administered concomitantly .
effect	interactions with other cns agents : concomitant use of <e11> drug1 </e11> with other cns _ depressants ( e , g , , alcohol , <e22> drug2 </e22> , sedatives , hypnotics , other anesthetics , general anesthetics ) may result in an additive cns depression .
effect	<e12> drug1 </e12> can increase the antihypertensive effect of <e22> drug2 </e22> such as reserpine , cimetidine , and enalapril .
effect	in post - marketing experience , there have been isolated reports of severe hypokalemia and cardiac arrhythmias in patients receiving <e12> drug1 </e12> concomitantly with <e20> drug2 </e20> .
effect	concurrent administration of <e10> drug1 </e10> with <e20> drug1 </e20> ( with or without calcium _ channel _ blockers ) may increase toxicity .
effect	in some patients , the concomitant use of <e12> drug1 </e12> with <e22> drug2 </e22> may increase the risk of serotonin syndrome .
effect	administration of # - mg / kg <e10> drug1 </e10> to rats caused additive effects with <e20> drug2 </e20> .
effect	in some patients , however , the concomitant use of other <e12> drug1 </e12> with <e20> drug2 </e20> may have an additive effect on bleeding .
effect	however , the systemic administration of <e12> drug1 </e12> can potentiate the effects of <e22> drug2 </e22> , including dipyridamole , in a dose - dependent manner .
effect	nephrotoxicity has been reported when <e11> drug1 </e11> was administered concurrently with other <e22> drug2 </e22> .
effect	ace _ inhibitors and angiotensin _ ii _ receptor _ antagonists : <e11> drug1 </e11> can reduce the diuretic effect of <e22> drug2 </e22> and norepinephrine .
effect	administration of <e12> drug1 </e12> to patients receiving <e22> drug2 </e22> can prolong the qtc interval and increase the risk of ventricular tachycardia or arrhythmia .
effect	serious anticholinergic symptoms have been reported when <e10> drug1 </e10> was used concomitantly with nonsteroidal _ anti - inflammatory _ drugs ( <e22> drug2 </e22> ) .
effect	nephrotoxicity has been reported in patients receiving oral <e12> drug1 </e12> concomitantly with <e20> drug2 </e20> , and it has been suggested that the concomitant use of drug1 with drug2 may result in increased risk of nephrotoxicity .
effect	nephrotoxicity has been reported in patients receiving combination therapy with <e11> drug1 </e11> and <e22> drug2 </e22> .
effect	therefore the , combination of <e10> drug1 </e10> and <e20> drug2 </e20> may increase the risk of developing adrenal hyperplasia and other adrenal tumors .
effect	vaccines : patients taking <e12> drug1 </e12> may be at increased risk of developing thromboembolic complications when <e22> drug2 </e22> are given concomitantly .
effect	butalbital , <e10> drug1 </e10> and dextromethorphan , but not dextrorphan , enhanced the responses to the amphetamine _ type _ rho _ antagonist , <e21> drug2 </e21> .
effect	furosemide : clinical studies in dogs and humans have shown that <e10> drug1 </e10> can potentiate the hypotensive effect of <e22> drug2 </e22> .
effect	imidazoles ( e , g , , <e10> drug1 </e10> ) and succinylcholine may enhance the effects of <e22> drug2 </e22> such as alcohol .
effect	<e11> drug1 </e11> may increase the effect of nonsteroidal _ anti - inflammatory _ agents ( <e22> drug2 </e22> ) such as ibuprofen .
effect	administration of <e10> drug1 </e10> may prolong the action of <e22> drug2 </e22> and phenothiazines .
effect	<e10> drug1 </e10> may decrease the effects of <e22> drug2 </e22> , including alcohol , barbiturates and tranquilizers .
effect	severe hypoglycemia has been reported following coadministration of <e12> drug1 </e12> with drugs such as monoamine _ oxidase _ inhibitors ( maois ) and <e22> drug2 </e22> .
effect	consider additive sedative effects when <e12> drug1 </e12> and <e22> drug2 </e22> are used concomitantly .
effect	<e10> drug1 </e10> and other psychotropics may decrease the efficacy of <e22> drug2 </e22> , and it is recommended that the drug2 be used with extreme caution in patients being treated with methamphetamines .
effect	drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , and <e20> drug2 </e20> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
effect	the antihypertensive effects of <e10> drug1 </e10> may be potentiated by some other <e22> drug2 </e22> .
effect	other drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , and sodium _ colistimethate ) , magnesium salts , <e22> drug2 </e22> injections , local anesthetics , procainamide , and quinidine .
effect	additive adverse effects including hypotension , bradycardia , and renal impairment have been reported with concomitant use of <e11> drug1 </e11> and other <e22> drug2 </e22> .
effect	the effectiveness of the <e12> drug1 </e12> is diminished by certain drugs ( eg , nonsteroidal _ anti - inflammatory _ agents , corticosteroids , and <e22> drug2 </e22> ) or by certain concurrent medications ( eg , salicylates ) .
effect	<e10> drug1 </e10> and other maois , when coadministered with other <e22> drug2 </e22> , may increase cns depression and potentially result in severe hypotension .
effect	drug2 : reports have suggested that <e10> drug1 </e10> may potentiate the cardiovascular effects of <e22> drug2 </e22> , as evidenced by decreased heart rate and elevated blood pressure .
effect	other drugs which may enhance the neuromuscular blocking action of <e10> drug1 </e10> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , lincomycin , clindamycin , colistin , and sodium _ colistimethate ) , magnesium salts , <e22> drug2 </e22> , procainamide , and quinidine .
effect	<e12> drug1 </e12> , including methoxy _ quinolones , may enhance the effect of other <e22> drug2 </e22> , especially potassium - sparing _ diuretics .
effect	nephrotoxicity has been reported in patients receiving <e12> drug1 </e12> concomitantly with <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may decrease the effect of other <e22> drug2 </e22> and may increase the effect of alcohol .
effect	the concomitant use of other anticholinergics ( <e10> drug1 </e10> , cyclopropane , drug1 _ methyl ) , other antidepressants , phenothiazines , tranquilizers , skeletal _ muscle _ relaxants , or other cns _ depressants ( including alcohol ) may cause severe , prolonged hypotension , which may necessitate the discontinuation of <e21> drug2 </e21> therapy .
effect	the concurrent administration of <e10> drug1 </e10> and <e22> drug2 </e22> is likely to produce additive effects , and the concomitant administration of an ssri ( e , g , , fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine , venlafaxine _ hcl ) may produce additive effects .
effect	<e12> drug1 </e12> may potentiate the neuromuscular blocking action of certain nsaids , including other nonsteroidal _ anti - inflammatory _ drugs ( <e22> drug2 </e22> ) , magnesium salts , non - steroidal _ anti - inflammatory _ drugs ( nsaids ) , corticosteroids , and beta _ adrenergic _ blocking _ agents .
effect	rarely drug2 toxicity has been reported in patients receiving <e11> drug1 </e11> concomitantly with <e20> drug2 </e20> .
effect	drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e20> drug2 </e20> , and sodium _ colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
effect	drugs which may enhance the neuromuscular blocking action of <e10> drug1 </e10> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , lincomycin , clindamycin , colistin , and sodium _ colistimethate ) , magnesium salts , lithium , local anesthetics , local anesthetics combined with general anesthetics , <e22> drug2 </e22> , quinidine , and steroids .
effect	<e10> drug1 </e10> may reduce the anticoagulant action of <e20> drug2 </e20> or coumarin derivatives .
effect	drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e22> drug2 </e22> ) , magnesium salts , local anesthetics , procainamide , quinidine , and vitamins _ d and e .
effect	drugs decreasing heparin effect : <e10> drug1 </e10> may increase the effect of <e22> drug2 </e22> such as heparin or warfarin .
effect	both ibogaine and <e10> drug1 </e10> produced pronounced and lasting antinociceptive effects when administered with <e21> drug2 </e21> and d - limonene .
effect	ace - inhibitors : reports suggest that <e12> drug1 </e12> may have a negative effect on <e20> drug2 </e20> - mediated blood pressure control .
effect	concomitant administration of <e10> drug1 </e10> - containing and <e20> drug2 </e20> - containing medications , such as drug2 , vasopressor s or other sympathomimetic _ drugs , may result in increased uterine contraction and the need for further drugs to control uterine contractions .
effect	preliminary data which suggests that the effects of <e11> drug1 </e11> may be additive with those of alcohol and other cns _ depressants such as <e22> drug2 </e22> , barbiturates , and sedative - hypnotics may be cause for concern .
effect	drug1 : <e10> drug1 </e10> may enhance the cns - depressive effects of alcohol , barbiturates , <e22> drug2 </e22> , or other cns _ depressants , and may cause cns depression .
effect	<e12> drug1 </e12> may inhibit platelet function in patients receiving <e22> drug2 </e22> or antiplatelet _ agents .
effect	in rats , simultaneous administration of <e10> drug1 </e10> and <e20> drug2 </e20> ( 40 mg / kg , p . o . ) caused a marked prolongation of the latency to escape and the number of escape attempts .
effect	<e10> drug1 </e10> has been shown to potentiate the drug2 effects of other <e22> drug2 </e22> _ drugs .
effect	<e10> drug1 </e10> may enhance the sedative effect of alcohol , barbiturates , general anesthetics , <e22> drug2 </e22> and other cns _ depressants .
effect	<e10> drug1 </e10> has been reported to decrease the anticholinergic effect of <e22> drug2 </e22> , including dipyridamole , and to increase the anticholinergic effect of the general anesthetics , including general anesthetics .
effect	oral <e12> drug1 </e12> may enhance the effectiveness of <e22> drug2 </e22> - containing antineoplastic _ agents .
effect	however , there has been one case report of the development of renal failure in a patient receiving <e10> drug1 </e10> concomitantly with <e22> drug2 </e22> .
effect	antagonism has been observed when <e10> drug1 </e10> and <e22> drug2 </e22> were used concomitantly .
effect	the administration of <e10> drug1 </e10> can prolong the qt interval when given with <e22> drug2 </e22> , including those with nonselective beta - blockers .
effect	<e10> drug1 </e10> may decrease the effect of certain <e22> drug2 </e22> and hypnotics .
effect	catecholamine - depleting agents : patients receiving <e10> drug1 </e10> concomitantly with agents that affect the nervous system ( e , g , , <e22> drug2 </e22> ) may exhibit elevations in blood pressure .
effect	anticholinergics : concurrent use of <e11> drug1 </e11> with anticholinergic _ agents ( eg , antipsychotics , tricyclic _ antidepressants , and <e22> drug2 </e22> ) has been reported to result in additive cns depressant effects .
effect	intraventricular injection of <e10> drug1 </e10> may potentiate the effects of <e22> drug2 </e22> .
effect	therefore , concurrent use of <e10> drug1 </e10> with other <e22> drug2 </e22> ( tricyclic _ antidepressants , antipsychotics , other antidepressants , and theophylline ) may produce additive cns depression .
effect	the administration of <e10> drug1 </e10> may reduce the effects of <e22> drug2 </e22> , alcohol , antianxiety _ agents and other cns _ depressants .
effect	the hypoglycemic action of <e10> drug1 </e10> may be enhanced by the concomitant use of <e22> drug2 </e22> , including other sulfonylurea _ drugs , such as sulfonylurea _ mesylate , and others .
effect	since <e10> drug1 </e10> may increase the response to <e22> drug2 </e22> , concomitant administration of both drugs should be avoided .
effect	the antihypertensive effects of <e10> drug1 </e10> and aminoglycosides are reduced by <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may enhance the effects of other nsaids , <e22> drug2 </e22> , and tricyclic _ antidepressants .
effect	- the action of <e10> drug1 </e10> can be antagonized by <e22> drug2 </e22> and other agents that inhibit the enzyme phosphatase , but not by beta - adrenergic _ blocking _ agents , calcium _ channel _ blockers , and antihistamines .
effect	in addition to the hypoglycemic action of insulin , oral <e12> drug1 </e12> may potentiate the hypoglycemic action of oral <e22> drug2 </e22> such as insulin .
effect	an additive hypotensive effect with <e10> drug1 </e10> may occur with <e20> nor drug1 </e20> .
effect	the adverse effects of <e10> drug1 </e10> are augmented by oral <e22> drug2 </e22> such as aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , and sodium _ colistimethate .
effect	as with some other narcotic _ analgesic s , the administration of <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> , carbamazepine , or other opioids may increase the risk of respiratory depression .
effect	diuretics : patients receiving concomitant use of <e11> drug1 </e11> with <e22> drug2 </e22> ( e , g , , salt and / or salt with potassium - sparing _ drug2 ) may have an increased risk of hypokalemia .
effect	the ecg changes induced by <e10> drug1 </e10> were enhanced by <e20> drug2 </e20> .
effect	isoflurane or <e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> .
effect	the vasodilating effects of <e10> drug1 </e10> may be potentiated by <e22> drug2 </e22> .
effect	- drugs whose efficacy has been shown to be diminished by <e11> drug1 </e11> include : thiazides , <e22> drug2 </e22> , corticosteroid _ derivatives , azathioprine , coumarin , vitamin _ d , and beta _ adrenergic _ blocking _ agents .
effect	thus , the results obtained in these studies indicate that <e10> drug1 </e10> may enhance the effect of <e22> drug2 </e22> in patients .
effect	<e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> , including alcohol , barbiturates , general anesthetics , opioids , sedatives , tranquilizers , or theophylline .
effect	animal experience indicates that <e10> drug1 </e10> can enhance the cns effects of <e22> drug2 </e22> and alcohol .
effect	drugs that reduce the neuromuscular blocking action of <e10> drug1 </e10> include those of the anesthetics , narcotic _ analgesic , barbiturates , general anesthetics , phenothiazines , the serotonergic _ agents <e22> drug2 </e22> and the drug2 ( see clinical pharmacology ) .
effect	anesthetics / sedatives / hypnotics : in clinical studies , <e11> drug1 </e11> demonstrated increased cns depression when administered with <e20> drug2 </e20> , sedatives , and hypnotics .
effect	patients receiving other cns _ depressants ( e , g , , alcohol , barbiturates , <e12> drug1 </e12> , sedatives , or anesthetics ) concomitantly with <e21> drug2 </e21> may exhibit additive cns depressant effects .
effect	drugs which may enhance the neuromuscular blocking action of <e12> drug1 </e12> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , polymyxins , lincomycin , clindamycin , <e20> drug2 </e20> , and sodium _ colistimethate ) , magnesium salts , local anesthetics , procainamide , and quinidine .
effect	the concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> may increase the risk of gastrointestinal ulceration .
effect	injection : <e10> drug1 </e10> may enhance the effects of other opioids , <e22> drug2 </e22> , general anesthetics , phenothiazines , tranquilizers such as chlordiazepoxide , and other cns _ depressants , causing increased cns depression .
effect	other cns _ depressant _ drugs ( e , g , barbiturates , tranquilizers , general anesthetics , and <e12> drug1 </e12> ) may potentiate the neuromuscular blocking action of <e22> drug2 </e22> .
effect	certain drugs , including <e10> drug1 </e10> , may potentiate the hypoglycemic action of <e22> drug2 </e22> .
effect	blunting of the nitric oxide - mediated vasodilator response has been observed when <e11> drug1 </e11> and <e20> drug2 </e20> are coadministered .
effect	although this effect has not been studied in dogs , given the similarity in the pharmacology of <e12> drug1 </e12> and <e22> drug2 </e22> , the possibility of additive cns depression by the two classes of drugs may be of importance .
effect	drug interactions : the cns depression resulting from the combined administration of <e11> drug1 </e11> and <e22> drug2 </e22> may include , but are not limited to , increased sedation , hallucinations , convulsions , coma , and even death .
effect	<e12> drug1 </e12> , such as warfarin or its derivatives , may enhance the effects of <e22> drug2 </e22> - type _ anticoagulants , including those used for anticoagulant prophylaxis or prophylaxis of bleeding .
effect	however , <e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> , tricyclic _ antidepressants , and other cns _ depressants .
effect	<e10> drug1 </e10> enhances the effects of the anticholinergic _ agents <e22> drug2 </e22> and antihistamines .
effect	interactions with other cns agents : concurrent use of <e11> drug1 </e11> with cns _ depressants such as alcohol , barbiturates , <e22> drug2 </e22> , opiates , sedatives , or other cns _ depressants may result in additive cns depression .
effect	drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e10> drug1 </e10> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e20> drug2 </e20> , colistin , and sodium _ colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , quinidine , and certain phenothiazines .
effect	<e10> drug1 </e10> potentiates the anticholinergic effects of <e22> drug2 </e22> .
effect	both the magnitude and duration of the antihypertensive effect of <e11> drug1 </e11> were significantly attenuated by <e20> drug2 </e20> and haloperidol .
effect	<e10> drug1 </e10> attenuates the hypotensive effects of alcohol , nor drug2 , <e20> drug2 </e20> , and nor drug2 _ hcl .
effect	the hypoglycemic action of all <e12> drug1 </e12> may be antagonized by inhibitors of insulin and glucagon secretion , including sulfonylurea _ insecticides ( e , g , , bactroban ) , sulfonylurea _ drugs ( e , g , , <e20> drug2 </e20> ) , and oral hypoglycemic _ agents .
effect	<e10> drug1 </e10> may decrease the vasodilator effect of <e22> drug2 </e22> or nitrates .
effect	as with other <e12> drug1 </e12> , when used concomitantly with <e22> drug2 </e22> , certain individuals may develop marked sedative - hypnotic effects .
effect	selective _ serotonin _ reuptake _ inhibitors ( ssris ) and <e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> , including other antidepressants , haloperidol , thioridazine , risperidone , and drug1 .
effect	furosemide : clinical studies have shown that <e12> drug1 </e12> may increase the anticoagulant effects of <e20> drug2 </e20> .
effect	the vasodilating effects of <e11> drug1 </e11> may be enhanced by : certain antihypertensive _ drugs , antihypertensive _ complexes , certain antibiotics , and <e22> drug2 </e22> .
effect	ssris : weakness , vertigo , or severe headache have been reported with concomitant use of <e11> drug1 </e11> and <e22> drug2 </e22> .
effect	noncardioselective _ beta - blockers ( <e10> drug1 </e10> or nor drug1 ) may reduce the effects of <e20> drug2 </e20> .
effect	- although not studied in patients receiving <e11> drug1 </e11> , the use of <e20> drug2 </e20> ( # mg / kg , # times a day ) may result in increased intracellular calcium concentrations .
effect	interactions with other cns agents : the cns - depressant effects of the <e12> drug1 </e12> ( e , g , , alprazolam , diazepam , and chlordiazepoxide ) may be additive with those of other central _ nervous _ system _ depressants , including other opioids , barbiturates , sedatives , tranquilizers , or <e22> drug2 </e22> .
effect	drug1 : <e10> drug1 </e10> may enhance the neuromuscular blocking action of <e22> drug2 </e22> .
effect	administration of <e12> drug1 </e12> in combination with <e22> drug2 </e22> ( e , g , , tricyclic _ antidepressants , such as nortriptyline , amitriptyline , and imipramine ) , drug2 , antianxiety _ agents , tricyclic _ antidepressants , or other cns _ depressants may potentiate cns depression .
effect	vasopressor s : <e10> drug1 </e10> may reduce the efficacy of <e22> drug2 </e22> s .
effect	<e12> drug1 </e12> can potentiate the effects of certain <e22> drug2 </e22> .
effect	drug1 reports suggest that <e12> drug1 </e12> may potentiate the antihypertensive effect of <e20> drug2 </e20> .
effect	in patients receiving both <e10> drug1 </e10> and <e22> drug2 </e22> , the concomitant use of an intravenous ( iv ) drug1 infusion rate of more than 2 microg / kg per minute and a low drug1 dose ( 0 . 15 microg / kg ) was associated with increased ventricular fibrillation .
effect	the antihypertensive effects of <e10> drug1 </e10> are diminished by the concurrent administration of <e22> drug2 </e22> .
effect	in common with other sympathomimetic _ drugs , <e10> drug1 </e10> may potentiate the effects of <e20> drug2 </e20> and the phenothiazines .
effect	<e10> drug1 </e10> may enhance the cns depressant effects of alcohol , barbiturates , <e22> drug2 </e22> , general anesthetics , tranquilizers , or other drugs that produce central nervous system depression .
effect	- <e10> drug1 </e10> may enhance the effects of other narcotic _ analgesic s , including sedatives , general anesthetics , tranquilizers , and <e22> drug2 </e22> s .
effect	uricosuric _ agents : <e11> drug1 </e11> has been reported to enhance the effects of <e22> drug2 </e22> .
effect	concurrent use of <e10> drug1 </e10> and <e20> drug2 </e20> ( a monoamine oxidase _ inhibitor ) has been reported to result in a similar increase in tachypnea and apnea .
effect	<e10> drug1 </e10> may increase the effect of <e22> drug2 </e22> and other drugs that are less anti - inflammatory than digoxin .
effect	central _ nervous _ system _ depressants : the potential effects of <e10> drug1 </e10> and other opioids on central nervous system depressants , including alcohol , barbiturates and other narcotic _ analgesic s , and other <e22> drug2 </e22> may be potentiated by these drugs .
effect	drug1 : <e10> drug1 </e10> salts are potentiated the inhibitory effects of <e22> drug2 </e22> and the hypotensive effects of norepinephrine in guinea pigs .
effect	<e11> drug1 </e11> may potentiate the anticholinergic effects of antipsychotic _ agents , including <e22> drug2 </e22> , phenothiazines , and other agents having anticholinergic activity .
effect	( in some patients , the use of <e10> drug1 </e10> may have resulted in increased toxicity , and the concomitant use of <e20> drug2 </e20> may have been associated with increased toxicity .
effect	concurrent administration of <e12> drug1 </e12> with <e22> drug2 </e22> may increase the risk of pulmonary toxicity .
effect	ventricular tachycardia induced by administration of <e10> drug1 </e10> may be potentiated by <e22> drug2 </e22> .
effect	cytotoxic _ agents : enhanced cns toxicity may be induced by <e11> drug1 </e11> in patients receiving concomitant administration of an oral <e22> drug2 </e22> and potent antitumor agents .
effect	<e13> drug1 </e13> attenuates the antinociceptive effects of <e20> drug2 </e20> and other opiates .
effect	concurrent use of <e10> drug1 </e10> and <e20> drug2 </e20> may increase the risk of respiratory depression .
effect	<e10> drug1 </e10> may enhance the cns - depressive action of <e22> drug2 </e22> or other drugs .
effect	the administration of high doses of <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> may produce severe reactions , including serotonin syndrome .
effect	in a study in healthy volunteers , <e10> drug1 </e10> produced dose - related decreases in pulse and arterial pressure and increases in blood pressure when given with <e20> drug2 </e20> .
effect	<e10> drug1 </e10> may diminish the anticoagulant action of <e22> drug2 </e22> , such as warfarin or its derivatives .
effect	- indomethacin : coadministration of <e10> drug1 </e10> and <e20> drug2 </e20> produced additive toxic effects .
effect	h2 _ blockers / proton _ pump _ inhibitors : clinical studies indicate that the concomitant use of <e11> drug1 </e11> and <e20> drug2 </e20> may result in an increased risk of hypokalemia .
effect	data suggest that <e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> and other medications that cause increases in serum prothrombin time .
effect	the use of <e10> drug1 </e10> or its derivatives may increase the effects of <e22> drug2 </e22> such as alcohol , barbiturates and narcotic _ analgesics .
effect	uricosuric _ agents : <e11> drug1 </e11> may enhance the cns depressant effects of certain <e22> drug2 </e22> .
effect	""" other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium _ colistemethate ) , magnesium salts , lithium , local anesthetics , procainamide , quinidine , <e22> drug2 </e22> , and unspecified "" "" histamines "" "" ( e , g , , methyldopa , butyrophenone , phenylbutazone , clorithromycin , dextromethorphan , dextrorphan ) . """
effect	as with some other <e12> drug1 </e12> , the administration of <e22> drug2 </e22> or drug1 may prolong the qt interval .
effect	there are rare reports of hepatotoxicity in patients taking <e10> drug1 </e10> concomitantly with <e22> drug2 </e22> .
effect	the use of other narcotic _ analgesic s such as butorphanol , diclofenac and <e10> drug1 </e10> can potentiate the cns depressant effects of <e21> drug2 </e21> .
effect	it is , however , possible that a dose - dependent increase in cns depression may occur when <e10> drug1 </e10> is administered concurrently with <e22> drug2 </e22> .
effect	epidemiological studies of patients on drug2 such as <e10> drug1 </e10> may indicate an increased risk of gastrointestinal ulceration when administered with <e22> drug2 </e22> .
effect	drug1 : <e10> drug1 </e10> can reduce the antihypertensive effect of <e20> drug2 </e20> by blocking its direct vasodilator action .
effect	hypersensitivity reactions have been reported to occur when <e12> drug1 </e12> are administered concomitantly with <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may have additive cns - depressive effects with other <e22> drug2 </e22> .
effect	ace _ inhibitors : reports indicate that <e10> drug1 </e10> may enhance the effects of <e20> drug2 </e20> and other statins .
effect	drug1 - <e10> drug1 </e10> might enhance the effects of <e20> drug2 </e20> and alcohol .
effect	the concurrent use of <e10> drug1 </e10> with other opioids and <e22> drug2 </e22> may increase respiratory depression , and the concomitant use of other opioids with drug2 may prolong the qtc interval .
effect	nephrotoxicity has been reported with concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> .
effect	in a small number of patients , the effects of <e10> drug1 </e10> have been reported to be additive with those of other narcotic _ analgesic s , including <e22> drug2 </e22> .
effect	potassium supplements and other potassium - sparing _ drugs : patients receiving <e10> drug1 </e10> and other potassium - sparing _ drugs may experience an increase in serum potassium levels when the drugs are given with <e20> drug2 </e20> .
effect	<e10> drug1 </e10> may enhance the antinociceptive effect of other opioids , barbiturates , tranquilizers , general anesthetics , <e22> drug2 </e22> , and tricyclic _ antidepressants , leading to increased analgesia .
effect	catecholamine - depleting drugs , e , g , , <e10> drug1 </e10> , may potentiate the hypotensive effects of <e22> drug2 </e22> .
effect	tissue culture and serum studies showed that <e12> drug1 </e12> may enhance the anticoagulant effect of <e22> drug2 </e22> .
effect	the effect of the combined use of these <e12> drug1 </e12> and <e20> drug2 </e20> in patients undergoing major surgery may be additive .
effect	patients receiving other antipsychotic _ agents ( e , g , , other antidepressants , <e10> drug1 </e10> , thioridazine , phenothiazines , etc , ) concomitantly with <e21> drug2 </e21> may exhibit an additive effect .
effect	( <e12> drug1 </e12> may enhance the effect of <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may enhance the neuromuscular blocking action of <e22> drug2 </e22> , such as phenothiazines , butyrophenones , or drug2 , such as the antihistamine chlordiazepoxide .
effect	in some patients , the combination of an <e12> drug1 </e12> and an <e22> drug2 </e22> has been shown to result in hypotension .
effect	benazepril , like other <e12> drug1 </e12> , may potentiate the sympathomimetic effects of <e20> drug2 </e20> .
effect	seizures have been reported with concomitant use of <e11> drug1 </e11> and <e20> drug2 </e20> .
effect	other drugs which may enhance the neuromuscular blocking action of <e10> drug1 </e10> include certain antibiotics ( e , g , , <e22> drug2 </e22> , polymyxins , tetracyclines , drug2 , polymyxins _ sodium , polymyxins _ potassium , lincomycin , and clindamycin ) , magnesium salts , local anesthetics , procainamide , and quinidine .
effect	drugs which may enhance the neuromuscular blocking action of <e12> drug1 </e12> such as epinephrine include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , lincomycin , <e20> drug2 </e20> , colistin , drug2 , colistin , and sodium _ colistimethate ) , magnesium salts , local anesthetics , procainamide , quinidine , succinylcholine , and theophylline .
effect	profound hypotensive episodes have been reported in patients receiving <e10> drug1 </e10> concomitantly with <e20> drug2 </e20> .
effect	nephrotoxicity has been reported when <e11> drug1 </e11> was administered concurrently with potent antineoplastic _ agents such as <e20> drug2 </e20> and carboplatin .
effect	1 - adrenergic receptor _ blocking _ agents ( <e10> drug1 </e10> ) attenuate the hypoglycemic action of <e22> drug2 </e22> .
effect	central _ nervous _ system _ depressants : the concomitant use of an mao _ inhibitor ( e , g , , <e10> drug1 </e10> ) with <e22> drug2 </e22> ( e , g , , alcohol , barbiturates , sedatives , general anesthetics , opioids , or tricyclic _ antidepressants ) may produce cns depression , and concomitant administration of an mao _ inhibitor with any of these drugs may result in increased cns depression .
effect	<e10> drug1 </e10> and other salicylates may reduce the antihypertensive effect of <e20> drug2 </e20> and other salicylates .
effect	- antihypertensives : concomitant administration of <e10> drug1 </e10> with agents known to prolong the qt interval ( e , g , , <e20> drug2 </e20> , reserpine and ephedrine ) has been associated with increased arrhythmia incidence .
effect	the administration of phenothiazines or other <e12> drug1 </e12> to patients receiving oral <e22> drug2 </e22> may result in the development of hypoglycemia .
effect	therapeutic drug monitoring ( dotimex ) and treatment discontinuation ( chemex ) studies of <e10> drug1 </e10> in combination with <e22> drug2 </e22> have shown that vasodilation is impaired in some patients .
effect	aspirin : animal studies have shown that the combination of <e11> drug1 </e11> with <e20> drug2 </e20> can result in a higher incidence of gastrointestinal ulceration than either drug alone .
effect	in some patients , <e10> drug1 </e10> may have an additive effect with <e20> drug2 </e20> .
effect	agents causing renin release : the vascular effects of <e11> drug1 </e11> may be potentiated by certain drugs including aspirin , other <e22> drug2 </e22> , local anesthetics , corticosteroids , and other drugs that are vasoconstrictive .
effect	our data suggest that alcohol consumption and <e10> drug1 </e10> may potentiate the central nervous system depressant effects of <e22> drug2 </e22> .
effect	<e10> drug1 </e10> pretreatment inhibited myocardial function by approximately 30 % and produced bradycardia and hypotension when given with <e20> drug2 </e20> or hydralazine .
effect	in a phase ii clinical trial , <e10> drug1 </e10> was shown to decrease the antihypertensive effect of <e22> drug2 </e22> in patients with moderate to severe hypertension .
effect	isoflurane or <e10> drug1 </e10> may enhance the effect of <e22> drug2 </e22> , including certain non - steroidal _ anti - inflammatory _ agents and corticosteroids .
effect	patients who are concurrently treated with <e11> drug1 </e11> and an antihistamine , such as a <e22> drug2 </e22> ( tcas ) , may develop histamine toxicity .
effect	therefore , the efficacy of <e10> drug1 </e10> may be compromised in patients receiving concurrent <e22> drug2 </e22> therapy , including antihistamines , antihistamines , tricyclic _ antidepressants , and antianxiety _ agents .
effect	<e13> drug1 </e13> may enhance the effect of <e22> drug2 </e22> , antipsychotics , or other cns _ depressants , causing increased cns depression .
effect	hypotension , av conduction disturbances , and hypotension have been reported in patients receiving oral <e10> drug1 </e10> and <e20> drug2 </e20> therapy simultaneously .
effect	the effects of <e10> drug1 </e10> may be potentiated by anticoagulants , <e22> drug2 </e22> , nonsteroidal _ anti - inflammatory _ drugs , beta _ blockers or other drugs that interfere with platelet function .
effect	<e10> drug1 </e10> may enhance the effect of nonsteroidal _ anti - inflammatory _ drugs ( <e22> drug2 </e22> ) , corticosteroids , monoamine _ oxidase _ inhibitors , and beta _ adrenergic _ blocking _ agents .
effect	combinations of <e10> drug1 </e10> with <e22> drug2 </e22> ( tricyclic _ antidepressants and phenothiazines ) have been reported to result in additive cns depression .
effect	concurrent use of <e10> drug1 </e10> and <e22> drug2 </e22> ( e , g , , tricyclic _ antidepressants , phenothiazines , antipsychotics , antihistamines , sedative - hypnotics , thioxanthene _ derivatives , tranquilizers , etc , ) may produce additive cns depressant effects .
effect	the use of <e12> drug1 </e12> may be associated with some effects on the central nervous system , including sedative - hypnotic syndrome , the hallucinogenic effects of <e20> drug2 </e20> , and anticonvulsant effects .
effect	<e10> drug1 </e10> has additive effects with alcohol and <e22> drug2 </e22> , and may produce respiratory depression .
effect	cytotoxic _ agents : enhanced toxicity and decreased activity of <e11> drug1 </e11> may be seen with the concomitant use of other potent antitumor _ agents , including <e22> drug2 </e22> , itraconazole , cisapride , dapsone , cisapride _ sodium , and cisapride _ sodium _ hydrogen _ maleate .
effect	interactions with other cns agents : cns _ depressants ( e , g , , alcohol , barbiturates , opiates , <e12> drug1 </e12> , drug1 , hypnotics , general anesthetics ) may potentiate the antianxiety effects of <e22> drug2 </e22> .
effect	other drugs which may enhance the neuromuscular blocking action of <e10> drug1 </e10> include certain antibiotics ( e , g , , <e22> drug2 </e22> , tetracyclines , bacitracin , lincomycin , and sodium _ colistemethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
effect	however , <e10> drug1 </e10> may decrease the efficacy of <e20> drug2 </e20> and isoniazid .
effect	<e10> drug1 </e10> may have an additive effect with <e20> drug2 </e20> and potassium salts when used in combination .
effect	1 - adrenergic receptor antagonists ( e , g , , <e10> drug1 </e10> and nor drug1 ) may enhance the cns - depressant effects of <e22> drug2 </e22> s .
effect	levodopa and amantadine : levodopa and <e10> drug1 </e10> may have additive depressant effects when coadministered with <e20> drug2 </e20> .
effect	in some patients , there have been reports of patients taking <e10> drug1 </e10> concomitantly with either <e22> drug2 </e22> or other drugs , resulting in the potential for serious , prolonged , hyperpyrexia .
effect	animal studies indicate that <e10> drug1 </e10> may enhance the cns - depressive effect of alcohol , <e22> drug2 </e22> , opiates , sedatives , or other drugs that produce cns depression .
effect	the effects of <e10> drug1 </e10> are additive with <e22> drug2 </e22> .
effect	synergism was observed in both <e10> drug1 </e10> and <e20> drug2 </e20> - induced contractile responses .
effect	epidural <e10> drug1 </e10> and local anesthetics may reduce the effects of <e22> drug2 </e22> .
effect	similarly , the effects of <e10> drug1 </e10> on the effects of <e22> drug2 </e22> may be potentiated by some drugs that are primarily metabolized by this isoenzyme , including certain antidepressants ( tricyclic _ antidepressants ) , phenothiazines , theophylline , and the barbiturates .
effect	however , reports suggest that <e12> drug1 </e12> may decrease the antihypertensive effect of other <e22> drug2 </e22> drugs .
effect	central _ nervous _ system _ depressants : the use of <e11> drug1 </e11> with certain central _ nervous _ system _ depressants ( eg , barbiturates , narcotic _ analgesics , general anesthetics , tricyclic _ antidepressants , phenothiazines , and <e22> drug2 </e22> ) may result in additive cns depressant effects .
effect	marked symptomatic orthostatic hypotension has been reported in patients taking <e10> drug1 </e10> and <e20> drug2 </e20> .
effect	<e13> drug1 </e13> may enhance the cns - depressive action of <e22> drug2 </e22> , including the tricyclic _ drug2 such as fluoxetine , amitriptyline , and paroxetine .
effect	the <e12> drug1 </e12> have been shown to inhibit the effect of <e22> drug2 </e22> such as procainamide and procainamide _ glucuronide in rats , and potentiate the action of procainamide and procainamide _ glucuronide in humans .
effect	drug interactions : the cns - depressant properties of <e12> drug1 </e12> may be potentiated by certain narcotic _ analgesic s , alcohol , barbiturates , general anesthetics , tranquilizers such as chlordiazepoxide , and other <e22> drug2 </e22> .
effect	animal experience indicates that <e10> drug1 </e10> may enhance the central nervous system depressant effect of other drugs known to depress the central nervous system , including alcohol , barbiturates , general anesthetics , <e22> drug2 </e22> , and general tranquilizers , including alcohol , barbiturates , general anesthetics , salsalate , and thioperamide .
effect	<e10> drug1 </e10> may enhance the effects of other <e22> drug2 </e22> .
effect	anesthetics / sedatives : <e10> drug1 </e10> increases the sedative effect of <e22> drug2 </e22> , but the increased sedative effect is reversible upon discontinuation of the anesthetic .
effect	reports suggest that <e12> drug1 </e12> may potentiate the hypotensive effect of <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may prolong the qtc interval in patients receiving antiarrhythmics , antihistamines , or <e22> drug2 </e22> .
effect	<e12> drug1 </e12> may enhance the effects of some <e22> drug2 </e22> such as alcohol , barbiturates , general anesthetics , sedatives , tranquilizers , or other drug2 , resulting in an increased cns depression .
effect	anticoagulants including coumarin derivatives ( including quinidine ) , rifampin , <e12> drug1 </e12> , and warfarin may reduce the efficacy of <e20> drug2 </e20> .
effect	drugs which may enhance the neuromuscular blocking action of <e10> drug1 </e10> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium _ colistimethate ) , magnesium salts , <e22> drug2 </e22> , and quinidine .
effect	corticosteroids and <e10> drug1 </e10> may enhance the activity of <e22> drug2 </e22> .
effect	increased hepatotoxicity of <e11> drug1 </e11> may be observed when administered with <e22> drug2 </e22> such as corticosteroids , antihistamines , and antihistaminics .
effect	both ibogaine and <e10> drug1 </e10> reduce the effects of <e20> drug2 </e20> .
effect	concomitant treatment with <e10> drug1 </e10> and drugs that may enhance its cns effect , including alcohol , drug2 , <e22> drug2 </e22> , narcotic _ analgesics , phenothiazines , thioxanthene _ derivatives , and other central _ nervous _ system _ depressants , may result in an increased cns depression .
effect	coadministration of <e10> drug1 </e10> and <e20> drug2 </e20> may increase the risk of side effects .
effect	when administered concurrently , <e12> drug1 </e12> may decrease the effects of <e22> drug2 </e22> .
effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e10> drug1 </e10> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , lincomycin , <e20> drug2 </e20> , clindamycin , and sodium _ colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
effect	other drugs which may enhance the neuromuscular blocking action of <e10> drug1 </e10> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , lincomycin , <e22> drug2 </e22> , chlorthalidone , clindamycin , colistin , ciprofloxacin , diflunisal , diflunisal _ sodium , dextran ) , magnesium salts , local anesthetics , procainamide , quinidine , salsalate , salicylates , succinylcholine and nonsteroidal _ anti - inflammatory _ drugs .
effect	this appears to be the only <e12> drug1 </e12> to produce a decrease in cardiac output in the presence of <e22> drug2 </e22> .
effect	administration of <e10> drug1 </e10> to patients receiving <e20> drug2 </e20> or its derivatives , such as haloperidol , produces bradycardia , hypotension , and marked increase in blood pressure .
effect	<e13> drug1 </e13> and chloramphenicol ( alone or in combination ) may inhibit the growth of strains of enterococcus spp . and staphylococcus aureus that are sensitive to <e20> drug2 </e20> and ciprofloxacin .
effect	patients taking <e10> drug1 </e10> concomitantly with <e20> drug2 </e20> may have an increased risk of hypotension .
effect	furosemide : clinical studies have shown that <e10> drug1 </e10> may enhance the effect of <e22> drug2 </e22> , and studies in patients with cirrhosis have shown that drug1 may potentiate the effect of the nsaid .
effect	pharmacodynamic interactions : the cns - depressant action of the <e12> drug1 </e12> may be potentiated by the cns _ depressant _ drugs of <e22> drug2 </e22> , general anesthetics , barbiturates , narcotic _ analgesics , and antihistamines .
effect	( in some patients , there have been isolated reports of severe hypotension associated with concomitant administration of <e10> drug1 </e10> and <e22> drug2 </e22> , and there have been reports of patients receiving concomitant diltiazem therapy with hypotension and / or marked cardiac depression .
effect	beta - blockers , clonidine , and <e10> drug1 </e10> may potentiate the effects of <e22> drug2 </e22> .
effect	the concurrent use of <e11> drug1 </e11> and other <e22> drug2 </e22> , aspirin , corticosteroids , monoamine _ oxidase _ inhibitors ( maois ) , and alcohol has been associated with a few cases of hypertension , myocardial infarction , and renal failure .
effect	the administration of drugs that are antihypertensive in nature ( eg , <e10> drug1 </e10> and alfentanil ) can produce vasodilation that can be counteracted by <e22> drug2 </e22> .
effect	drug2 : weakness / weakness associated with <e10> drug1 </e10> may occur in patients receiving <e22> drug2 </e22> concomitantly .
effect	therefore , concurrent use of <e10> drug1 </e10> with <e20> drug2 </e20> may result in increased estrogenic effects .
effect	the pressor effects of <e10> drug1 </e10> may be enhanced by <e22> drug2 </e22> , such as verapamil , or antihypertensive _ drugs , such as losartan .
effect	the administration of high doses of <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> may have additive effects with those of other drug2 .
effect	some reports have shown that <e10> drug1 </e10> may enhance the effect of the <e22> drug2 </e22> , especially the diuretics , and that the antidiuretic effect of the tricyclic _ antidepressants may be enhanced by drug1 .
effect	rhabdomyolysis has been reported in patients receiving <e10> drug1 </e10> concomitantly with <e22> drug2 </e22> .
effect	spontaneous reports of cardiac arrhythmias have been reported in patients taking <e10> drug1 </e10> concomitantly with <e22> drug2 </e22> .
effect	therefore the , combination of <e12> drug1 </e12> with <e20> drug2 </e20> may be an additive effect .
effect	nonsteroidal _ anti - inflammatory _ agents ( nsaids ) : clinical studies have shown that <e10> drug1 </e10> can reduce the anti - inflammatory effect of <e20> drug2 </e20> and may potentiate the anti - inflammatory effect of oral contraceptives .
effect	it has been shown that oral <e10> drug1 </e10> can reduce the effects of alcohol , <e22> drug2 </e22> , and other psychotropic _ agents .
effect	in patients , the concomitant use of <e12> drug1 </e12> and <e20> drug2 </e20> may produce severe anemia , even when the anticoagulant is discontinued .
effect	<e10> drug1 </e10> inhibits <e20> drug2 </e20> - induced conduction disturbances .
effect	it is concluded that <e10> drug1 </e10> can produce hepatotoxicity when administered concomitantly with other <e22> drug2 </e22> .
effect	serious toxicity may result from concomitant use of <e11> drug1 </e11> and other <e22> drug2 </e22> s .
effect	however , the systemic effects of <e10> drug1 </e10> are enhanced by <e20> drug2 </e20> , and the effects of drug2 on the central nervous system may be potentiated by adrenergic _ agents such as drug2 .
effect	platelet _ inhibitors : drugs that inhibit platelet function ( such as aspirin and other <e12> drug1 </e12> ) have been reported to prolong the prothrombin time and enhance the effect of <e20> drug2 </e20> .
effect	dose - response curves ( derived from studies in rodents ) indicate that <e10> drug1 </e10> potentiates the cns - depressive effect of <e22> drug2 </e22> .
effect	<e11> drug1 </e11> may enhance the effects of other <e22> drug2 </e22> .
effect	there have been reports of severe reactions in patients receiving <e10> drug1 </e10> concomitantly with <e20> drug2 </e20> .
effect	since <e10> drug1 </e10> and <e20> drug2 </e20> , when administered concurrently , induce liver toxicity , coadministration of drug1 or drug2 with other drugs ( eg , certain anti - ulcer drugs , antineoplastic _ agents , corticosteroids , other beta - blockers , or oral contraceptives ) that produce hepatic toxicity , including certain antibiotics or other drugs ( eg , aminoglycosides , tetracyclines , bacitracin , clindamycin , colistin , cypermethrin , foscarnet , probenecid , quinidine , sirolimus , succinylcholine , and verapamil ) or that inhibit the activity of beta - blockers , such as apamin , may increase the risk of serious , prolonged , and / or adverse reactions .
effect	the hypoglycemic action of the <e12> drug1 </e12> may be potentiated by certain drugs including certain antibiotics , sulfonamides , <e22> drug2 </e22> , drug2 _ with _ b - blocking _ properties , thiazide _ diuretics , beta _ adrenergic _ blocking _ agents , beta _ blockers , and other drugs that reduce the contractile response to insulin .
effect	interactions with other cns agents : concurrent use of <e12> drug1 </e12> with other central _ nervous _ system _ depressants , including alcohol , drug1 , phenothiazines and other <e22> drug2 </e22> , may result in increased cns depression .
effect	<e10> drug1 </e10> may potentiate the actions of other <e22> drug2 </e22> , including alcohol , barbiturates , general anesthetics , opioids , sedative - hypnotics , and tranquilizers .
effect	paralytic ileus may occur when the <e12> drug1 </e12> are administered concomitantly with <e22> drug2 </e22> derivatives .
effect	<e12> drug1 </e12> can reduce blood pressure in some hypertensive patients by blocking the antihypertensive effect of the <e22> drug2 </e22> .
effect	central _ nervous _ system _ depressants : the effects of central _ nervous _ system _ depressants ( eg , <e12> drug1 </e12> ) on the central nervous system are reduced by <e20> drug2 </e20> .
effect	pyrazolone _ derivatives ( <e10> drug1 </e10> and nifedipine ) may increase the effects of other nonsteroidal _ anti - inflammatory _ drugs ( nsaids ) and <e22> drug2 </e22> .
effect	the concurrent use of <e10> drug1 </e10> with other <e22> drug2 </e22> ( eg , procainamide , drug1 , nor drug1 , and valdecoxib ) has been associated with additive effects .
effect	interactions with other cns agents : concurrent administration of <e12> drug1 </e12> with other cns _ depressants , including alcohol , barbiturates , tranquilizers such as <e22> drug2 </e22> , phenothiazines , and other drug1 may produce severe , prolonged hypotension and increased central nervous system depression .
effect	butalbital , acetaminophen , and <e10> drug1 </e10> may decrease the efficacy of <e22> drug2 </e22> .
effect	as with other sympathomimetic _ agents , <e10> drug1 </e10> may increase the effect of other <e22> drug2 </e22> .
effect	other drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , lincomycin , and clindamycin ) , magnesium salts , lithium , local anesthetics , <e22> drug2 </e22> , procainamide , and quinidine .
effect	other drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium _ colistimethate ) , magnesium salts , <e22> drug2 </e22> , local anesthetics , procainamide , and quinidine .
effect	the benzodiazepines , including <e10> drug1 </e10> , may enhance the cns depressant effects of other narcotic _ analgesic s , barbiturates , <e22> drug2 </e22> , drug2 , general tranquilizers , phenothiazines , psychotropics , sedative - hypnotics , or other cns _ depressants ( e , g , , alcohol , drug2 , barbiturates , opiates , sedatives , tranquilizers , etc ) .
effect	increased nephrotoxicity has been reported when <e10> drug1 </e10> and <e20> drug2 </e20> were administered concomitantly .
effect	the concurrent use of <e10> drug1 </e10> and <e20> drug2 </e20> may enhance the diuretic effect of drug2 .
effect	concomitant use of <e11> drug1 </e11> with alcohol or other cns _ depressants ( including narcotic _ analgesics , tranquilizers , <e22> drug2 </e22> , general anesthetics , etc , ) may result in additive cns depression .
effect	it is , however , possible that concomitant administration of <e12> drug1 </e12> and <e20> drug2 </e20> could cause severe respiratory depression .
effect	<e10> drug1 </e10> may reduce the blood pressure effects of <e22> drug2 </e22> .
effect	these pharmacokinetic effects may be additive , and <e10> drug1 </e10> may enhance the effects of nonsteroidal _ anti - inflammatory _ agents and other <e22> drug2 </e22> .
effect	- antihypertensives : concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> may result in additive cns depressant effects .
effect	seizures have been reported in patients taking <e12> drug1 </e12> concomitantly with <e22> drug2 </e22> , including phenytoin , carbamazepine , and phenobarbital .
effect	<e10> drug1 </e10> may reduce the antihypertensive effect of <e22> drug2 </e22> and other agents that produce renal excretion of salt , such as procainamide .
effect	these results suggest that <e10> drug1 </e10> may have a significant effect on the effects of <e20> nor drug1 </e20> .
effect	similarly , <e10> drug1 </e10> and <e20> drug2 </e20> potentiate the effects of the combined use of the above drugs .
effect	cyclosporine : because of the potential for additive cns depression when <e11> drug1 </e11> and <e20> drug2 </e20> are coadministered , the concomitant use of oral anticoagulants such as warfarin , similar to drug1 , is contraindicated .
effect	it is believed that the additive effects of <e10> drug1 </e10> and <e22> drug2 </e22> may increase the risk of seizures .
effect	<e10> drug1 </e10> may enhance the activity of <e22> drug2 </e22> , sympathomimetics , phenothiazines , or tricyclic _ antidepressants .
effect	- although not directly involved in its action , <e12> drug1 </e12> can block the antihypertensive effect of the beta - blocker <e22> drug1 </e22> .
effect	in single and multiple dose studies , coadministration of <e11> drug1 </e11> with oral <e22> drug2 </e22> ( e , g , , nonsteroidal _ anti - inflammatory _ drugs or non - steroidal _ anti - inflammatory _ biotics ) may have increased the potential for cns depressant effects .
effect	pharmacodynamic interactions : the cns - depressant action of <e11> drug1 </e11> may be potentiated by other cns _ depressants , including alcohol , barbiturates , <e22> drug2 </e22> , phenothiazines and general anesthetics .
effect	<e13> drug1 </e13> can also potentiate the antihypertensive effects of other <e22> drug2 </e22> .
effect	however , <e10> drug1 </e10> ( 40 mg / kg ) administered in combination with <e20> drug2 </e20> ( 50 mg / kg ) has additive effects in inhibiting tumor growth .
effect	the hypoglycemic action of <e10> drug1 </e10> may be potentiated by <e22> drug2 </e22> , such as drug2 , and by certain antibiotics such as cephalosporins , tetracyclines , and bacitracin .
effect	injection : <e10> drug1 </e10> has been shown to enhance the neuromuscular blocking effect of <e22> drug2 </e22> .
effect	in addition , <e10> drug1 </e10> has been reported to potentiate the effects of <e20> drug2 </e20> and other opioids .
effect	vasoconstrictors : <e11> drug1 </e11> may reduce the vascular effects of <e20> drug2 </e20> and insulin .
effect	patients who begin taking <e12> drug1 </e12> concomitantly with <e20> drug2 </e20> or other hormonal contraceptives may experience an increased risk of breast cancer .
effect	hypotension , av conduction disturbances , and av nodal conduction disturbances have been reported when <e11> drug1 </e11> was administered with or without other <e22> drug2 </e22> s .
effect	antihypertensives : <e12> drug1 </e12> may enhance the hypotensive effect of <e22> drug2 </e22> .
effect	the hypoglycemic action of <e10> drug1 </e10> may be potentiated by certain drugs including <e22> drug2 </e22> , barbiturates , local anesthetics , general anesthetics , phenothiazines , and antihistamines .
effect	in particular , convulsions and death have been reported when <e10> drug1 </e10> was added to <e20> drug2 </e20> or valdecoxib or to epinephrine alone .
effect	non - steroidal _ anti - inflammatory _ drugs : in some patients , concomitant administration of <e10> drug1 </e10> and non - steroidal _ anti - inflammatory _ drugs ( nsaids , <e22> drug2 </e22> ) may result in serious , sometimes fatal , reactions .
effect	antihistamines : <e12> drug1 </e12> may potentiate the cns depressant effects of <e22> drug2 </e22> .
effect	additionally , anti - malarial _ drugs , such as chloroquine and <e10> drug1 </e10> , may enhance the effect of <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may interfere with the liver retinoid response to <e22> drug2 </e22> and retinyl _ cysteine .
effect	<e10> drug1 </e10> may potentiate the vasodilating effects of other <e22> drug2 </e22> .
effect	furosemide : clinical studies have shown that <e10> drug1 </e10> increases the hypotensive effect of <e20> drug2 </e20> .
effect	increased nephrotoxicity has been observed when <e11> drug1 </e11> and <e20> drug2 </e20> are used concomitantly .
effect	other drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , clindamycin , colistin , sodium _ colistimethate , and <e22> drug2 </e22> ) ;
effect	preliminary clinical data have shown that the administration of <e12> drug1 </e12> to patients receiving <e22> drug2 </e22> may cause hypotension .
effect	drug interactions : the cns - depressant effect of <e11> drug1 </e11> may be potentiated by certain drugs including some <e22> drug2 </e22> and antidepressants , barbiturates and some general anesthetics , tricyclic _ antidepressants and narcotic _ analgesics , phenothiazines and tricyclic _ antidepressants , and beta _ adrenergic _ blocking _ agents .
effect	<e10> drug1 </e10> may enhance the effects of other <e22> drug2 </e22> s , including codeine , phenothiazines , thioxanthene , and diazepam .
effect	anti - arrhythmics and <e12> drug1 </e12> may potentiate the effect of <e20> drug2 </e20> .
effect	antagonism between <e10> drug1 </e10> and <e20> drug2 </e20> may occur .
effect	antihistamines : <e12> drug1 </e12> can increase the effect of <e22> drug2 </e22> , particularly dopamine _ agonists and phenothiazines .
effect	the antihypertensive effects of <e11> drug1 </e11> may be additive with those of other <e22> drug2 </e22> .
effect	rhabdomyolysis has been reported with concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> .
effect	spontaneous reports of severe angina have been reported in patients receiving concomitant <e12> drug1 </e12> and <e22> drug2 </e22> .
effect	the concomitant use of <e10> drug1 </e10> and other vasoconstrictor _ drugs , such as <e22> drug2 </e22> , may result in potentiating effects on cardiac function .
effect	there are rare reports of hypotension in patients receiving <e10> drug1 </e10> concomitantly with <e22> drug2 </e22> .
effect	<e10> drug1 </e10> also had additive effects with acetaminophen , caffeine , <e20> drug2 </e20> , and magnesium salts in reducing the number of painful sores induced by the intradermal injection of bromelain .
effect	serious toxicity may be seen when <e12> drug1 </e12> are used concomitantly with <e22> drug1 </e22> .
effect	in clinical trials , the addition of <e10> drug1 </e10> to the treatment of <e20> drug1 </e20> - induced toxicity has been associated with a reduction in toxicity .
effect	both the sedative and anticholinergic effects of <e10> drug1 </e10> may be potentiated by other narcotic _ analgesic s such as meperidine , butyrophenone , butyrophenone _ hydrochloride , procainamide , <e20> drug2 </e20> and drug2 .
effect	however , concomitant administration of <e10> drug1 </e10> with <e22> drug2 </e22> may increase respiratory depression and hypotension .
effect	as with other narcotic _ analgesic s , the effects of <e10> drug1 </e10> and <e22> drug2 </e22> may be additive .
effect	corticosteroids , methylxanthines and other drugs : in some patients , <e11> drug1 </e11> may produce severe hyperthermia , hypotension and severe renal impairment when administered concurrently with <e22> drug2 </e22> , methylxanthines or other drugs known to enhance the sympathetic nervous system .
effect	certain drugs , including <e12> drug1 </e12> , other anticoagulants , corticosteroids , monoamine _ oxidase _ inhibitors , and nonsteroidal _ anti - inflammatory _ agents may enhance the effects of <e21> drug2 </e21> .
effect	immediate and extended release tablets : concomitant use of <e10> drug1 </e10> with either <e22> drug2 </e22> or drug2 - like agents may produce a prolongation of the prothrombin time , which may be life - threatening .
effect	other tnfa - blocking _ agents ( including <e10> drug1 </e10> and ibandronate ) have been shown to reduce the hypotensive effect of <e21> drug2 </e21> .
effect	anticholinergics : concurrent administration of <e11> drug1 </e11> and drug2 ( <e22> drug2 </e22> ) can result in increased side effects such as erythema and hemorrhage .
effect	administration of <e10> drug1 </e10> may reduce the beneficial effects of <e22> drug2 </e22> .
effect	serious anticholinergic symptoms have been reported in patients receiving <e10> drug1 </e10> concomitantly with other anticholinergic _ drugs or anticholinergic _ injection _ systems ( eg , <e22> drug2 </e22> and other beta - adrenergic _ blocking _ agents ) .
effect	glyburide : the concomitant use of <e12> drug1 </e12> with an anti - inflammatory _ drug such as <e20> drug2 </e20> may lead to an additive cns - depressive effect .
effect	although not studied in a large number of patients , the results of studies with <e10> drug1 </e10> and <e22> drug2 </e22> suggest that combined use of both drugs may enhance the inflammatory effects of drug2 .
effect	<e12> drug1 </e12> and non - steroidal _ anti - inflammatory _ drugs ( nsaids ) may potentiate the cardiac effects of <e21> drug2 </e21> .
effect	<e13> drug1 </e13> can reduce the effects of opiates , <e22> drug2 </e22> , general anesthetics , and phenothiazines .
effect	similarly , <e10> drug1 </e10> can inhibit the <e20> drug2 </e20> - induced contraction of rat myocardium , which may be associated with its effect on sodium _ iodide symporter .
effect	both ibogaine and <e10> drug1 </e10> may reduce the effect of <e22> drug2 </e22> , sedatives , hypnotics , tranquilizers , phenothiazines , or other cns _ depressants .
effect	<e10> drug1 </e10> may enhance the effect of some <e22> drug2 </e22> s , including those that are primarily a neuromuscular blocking agent ( such as phenylbutazone ) and that do not depress the neuromuscular blocking action of a muscle relaxant ( such as dihydropyridine ) .
effect	in rats , simultaneous treatment with both <e10> drug1 </e10> and a single dose of <e20> drug2 </e20> ( 20 mg / kg ) decreased motor activity , while a single dose of drug2 alone did not alter motor activity in rats .
effect	the antihypertensive effects of <e11> drug1 </e11> may be potentiated by non - selective _ beta - blockers such as paroxetine and <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may potentiate the effects of <e22> drug2 </e22> and tricyclic _ antidepressants ( see clinical pharmacology ) .
effect	the concomitant use of <e10> drug1 </e10> with <e22> drug2 </e22> can potentiate the hypotensive effects of these agents .
effect	central _ nervous _ system _ depressants : the concomitant use of an ssri ( e , g , , fluoxetine , fluvoxamine , <e10> drug1 </e10> , sertraline , venlafaxine ) with certain cns _ depressants ( e , g , , barbiturates , opioids , <e22> drug2 </e22> ) may result in an additive cns depression .
effect	drug1 : <e10> drug1 </e10> has been reported to cause cardiac arrhythmias and to diminish the hypotensive effect of <e20> drug2 </e20> in some patients .
effect	aortic rings with aneurysms of the anterior descending artery ( 2 ) have been reported to have an increased tendency to rupture if <e10> drug1 </e10> is used concurrently with <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may enhance the cns depressant effects of alcohol , barbiturates , tranquilizers such as <e20> drug2 </e20> , sedatives such as chlorpromazine , or anesthetics such as halothane .
effect	other drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , lincomycin , clindamycin , colistin , and sodium _ colistemethate ) , magnesium salts , <e22> drug2 </e22> , and quinidine .
effect	it is possible that the combination of <e12> drug1 </e12> and <e20> drug2 </e20> might have an additive effect on arrhythmias , particularly those in the ventricular fibrillation ( vf ) or ventricular tachycardia ( vt ) region .
effect	injection of <e10> drug1 </e10> in association with local <e22> drug2 </e22> may have additive effects and produce postoperative confusion .
effect	dexamethasone and <e10> drug1 </e10> may synergistically enhance the effects of <e22> drug2 </e22> .
effect	concomitant use of certain <e12> drug1 </e12> with other drug1 , <e22> drug2 </e22> , salicylates , and other drugs that are extensively metabolized by this isozyme , including certain digitalis and diuretics , may increase the risk of gastrointestinal ulceration .
effect	patients who begin taking an anticonvulsant or other <e12> drug1 </e12> concurrently with <e21> drug2 </e21> may develop an additive cns depression .
effect	in addition , <e10> drug1 </e10> may enhance the effects of other <e22> drug2 </e22> .
effect	furosemide : clinical studies indicate that <e10> drug1 </e10> may reduce the efficacy of <e20> drug2 </e20> in a number of in vitro studies , possibly as a result of the concomitant increase in acid - base conditions .
effect	antidepressants , drug2 ( <e12> drug1 </e12> ) , and alcohol may enhance the cns depression produced by <e22> drug2 </e22> and alcohol .
effect	synergism has been reported when <e10> drug1 </e10> and <e20> drug2 </e20> were used together .
effect	concurrent use of <e10> drug1 </e10> with <e22> drug2 </e22> and other narcotic _ analgesics may result in increased cns depressant effects .
effect	beta - blockers , <e10> drug1 </e10> , and non - steroidal _ anti - inflammatory _ drugs may reduce the hypotensive effect of <e22> drug2 </e22> .
effect	inhibitors of endogenous serotonin reuptake inhibitors ( e , g , , <e10> drug1 </e10> ) ( e , g , , fluoxetine , fluvoxamine , paroxetine , sertraline ) may enhance the effects of <e22> drug2 </e22> .
effect	other drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium _ colistemethate ) , magnesium salts , <e22> drug2 </e22> , local anesthetics , procainamide , and quinidine .
effect	<e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> , salicylates , tricyclic _ antidepressants , phenothiazines , and beta _ blockers .
effect	hypersensitivity reactions have been reported in patients receiving <e10> drug1 </e10> with <e22> drug2 </e22> .
effect	deaths from severe renal dysfunction have occurred in patients treated with <e10> drug1 </e10> and <e22> drug2 </e22> .
effect	when <e10> drug1 </e10> is given concomitantly with certain <e22> drug2 </e22> , such as sedative - hypnotics , hypnotics , tranquilizers , or anesthetics , there has been a tendency to increase the risk of seizures .
effect	the <e13> drug1 </e13> - induced neurotoxicity was reversed by <e22> drug2 </e22> , and drug2 or caffeine augmented the neurotoxic effect of drug1 .
effect	in addition to reducing the risk of seizures , <e10> drug1 </e10> may reduce the stimulant effects of <e22> drug2 </e22> and other drugs that produce anticonvulsant effects .
effect	exogenous <e10> drug1 </e10> can reduce the vasodilator effect of <e22> drug2 </e22> .
effect	other cns _ depressant _ drugs ( e , g , barbiturates , tranquilizers , opioids , sedatives , <e12> drug1 </e12> ) and alcohol may enhance the cns _ depressant effects of <e21> drug2 </e21> .
effect	in patients receiving other drugs that may interfere with prostaglandin metabolism , concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> may result in increased adverse effects .
effect	intrathecal injection of <e12> drug1 </e12> may enhance the effect of <e21> drug2 </e21> .
effect	spontaneous reports of hyperpyrexia have been reported in patients receiving <e10> drug1 </e10> concomitantly with <e20> drug2 </e20> .
effect	tissue culture and in vivo studies suggest that <e10> drug1 </e10> may potentiate the activity of other <e22> drug2 </e22> .
effect	selective _ serotonin _ reuptake _ inhibitors ( ssris ) and other <e12> drug1 </e12> may increase the risk of severe , prolonged , unpredictable , or profound sedation or coma if administered concomitantly with <e21> drug2 </e21> .
effect	the hypotensive effect of <e10> drug1 </e10> may be potentiated by certain drugs including <e22> drug2 </e22> .
effect	antidepressants , drug2 and <e12> drug1 </e12> may enhance the antinociceptive action of <e22> drug2 </e22> , phenothiazines , and other narcotic _ analgesic s .
effect	administration of <e10> drug1 </e10> to patients taking <e22> drug2 </e22> , including patients receiving opioids , phenothiazines , or other cns _ depressants may produce severe hypotension and other cns depression symptoms .
effect	ace - inhibitors reports suggest that <e10> drug1 </e10> may reduce the beneficial effects of <e20> drug2 </e20> .
effect	warfarin : the concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> ( e , g , , coumarin , estragole ) may produce adverse reactions such as local and systemic toxicity .
effect	most of the analgesic _ agents , including <e10> drug1 </e10> , also produce sedation when administered with the <e22> drug2 </e22> or opioids .
effect	catecholamine - depleting drugs ( e , g , , <e10> drug1 </e10> ) may reduce the efficacy of <e20> drug2 </e20> .
effect	drug1 : <e10> drug1 </e10> may decrease the efficacy of <e20> drug2 </e20> .
effect	the concurrent use of <e10> drug1 </e10> and <e20> drug2 </e20> may produce an additive effect on the production of prostaglandins and thromboxane .
effect	<e10> drug1 </e10> has been shown to reduce the natriuretic effect of <e22> drug2 </e22> , epinephrine , and antihypertensive _ agents .
effect	drug1 : <e10> drug1 </e10> may enhance the anticholinergic effects of <e22> drug2 </e22> and other drugs with anticholinergic action .
effect	concurrent administration of <e10> drug1 </e10> and <e20> drug2 </e20> may result in additive depressant effects , which may include marked hyperreactivity to non - steroidal _ anti - inflammatory _ drugs and other sympathomimetic _ drugs .
effect	skeletal _ muscle _ relaxants : <e10> drug1 </e10> may inhibit skeletal _ muscle _ relaxant activity by additive effect with <e22> drug2 </e22> and alcohol .
effect	psychoactive _ drugs : hallucinations have been reported when <e11> drug1 </e11> was administered with psychoactive _ drugs ( e , g , , phenothiazines , thioxanthenes , <e22> drug2 </e22> , drug2 and tranquilizers )
effect	<e10> drug1 </e10> has been reported to enhance the anti - inflammatory action of <e22> drug2 </e22> , including hydrocortisone .
effect	the risk of hypotension associated with <e10> drug1 </e10> administration may be exacerbated by <e20> drug2 </e20> , benzodiazepines , non - steroidal _ anti - inflammatory _ agents , and other drugs which produce cns depression .
effect	injection : <e10> drug1 </e10> may enhance the effect of <e22> drug2 </e22> such as barbiturates and other anesthetics , as well as alcohol .
effect	the concurrent use of <e10> drug1 </e10> and <e22> drug2 </e22> has been associated with an increased risk of nephrotoxicity , but the relationship has not been studied in diabetic patients .
effect	butalbital , <e10> drug1 </e10> , and ethchlorvynol are reported to have additive cns - depressive effects when given in combination with <e22> drug2 </e22> , antidepressants , sedatives , or anesthetics .
effect	the concurrent use of <e10> drug1 </e10> and <e22> drug2 </e22> may result in increased anticholinergic effects , and concomitant use of other drugs which are also anticholinergic may increase the anticholinergic effects of drug1 .
effect	prolonged recovery time has been observed when <e10> drug1 </e10> was added to <e22> drug2 </e22> therapy .
effect	data suggest that certain <e12> drug1 </e12> may have an additive effect with <e22> drug2 </e22> .
effect	increased nephrotoxicity has been reported with coadministration of <e11> drug1 </e11> with <e22> drug2 </e22> and potassium - sparing _ diuretics .
effect	<e11> drug1 </e11> may enhance the effects of <e22> drug2 </e22> , sedatives , hypnotics , general anesthetics , tricyclic _ antidepressants , phenothiazines , tranquilizers , and other cns _ depressants .
effect	the benzodiazepines , including <e12> drug1 </e12> , may enhance the cns - depressive effects of <e20> drug2 </e20> and other central _ nervous _ system _ depressants .
effect	the effects of <e10> drug1 </e10> and <e20> drug2 </e20> may be additive .
effect	the antihypertensive effects of <e10> drug1 </e10> may be additive with <e22> drug2 </e22> .
effect	the hypoglycemic action of <e10> drug1 </e10> may be potentiated by other drugs including : certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , lincomycin , polymyxins , clindamycin , <e22> drug2 </e22> , and sodium _ colistimethate ) ; anticonvulsants , chloramphenicol ; calcium _ channel _ blockers ; local anesthetics ; nonsteroidal _ anti - inflammatory _ agents ; monoamine _ oxidase _ inhibitors ; paracetamol ; and unspecified antihypertensive _ drugs .
effect	drug1 - <e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> , phenothiazines , and narcotic _ analgesics .
effect	the blood pressure - lowering effect of <e11> drug1 </e11> may be enhanced by <e22> drug2 </e22> and diuretics .
effect	furosemide : clinical studies indicate that <e12> drug1 </e12> may potentiate the effects of <e22> drug2 </e22> .
effect	interactions with other cns agents : concurrent use of <e10> drug1 </e10> with other central _ nervous _ system _ depressants ( eg , barbiturates , <e22> drug2 </e22> , sedatives , and hypnotics ) has been associated with serious and sometimes fatal side effects , including convulsions , cns depression , and seizures .
effect	furosemide : clinical studies have shown that <e10> drug1 </e10> can decrease the effect of <e22> drug2 </e22> , including amikacin , and it is not known if drug1 affects amikacin pharmacokinetics .
effect	use of <e11> drug1 </e11> with other <e22> drug2 </e22> may potentiate convulsions .
effect	however , <e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may enhance the effect of <e22> drug2 </e22> , such as propofol and halothane .
effect	this allows <e10> drug1 </e10> to be less effective in the presence of <e20> drug2 </e20> .
effect	spontaneous reports of drug1 toxicity have been reported in a patient receiving concomitant <e10> drug1 </e10> and <e20> drug2 </e20> .
effect	the hypoglycemic effect of <e10> drug1 </e10> may be potentiated by certain <e22> drug2 </e22> including narcotic _ analgesics , phenothiazines , tranquilizers such as chlordiazepoxide and antihistamines .
effect	interactions with other cns agents : patients receiving other cns _ depressants ( e , g , , <e10> drug1 </e10> , barbiturates , sedatives , hypnotics , general anesthetics , phenothiazines , tranquilizers , or other cns _ depressants , including narcotic _ analgesics , tranquilizers , or other cns _ depressants , including antihistamines or other drugs of the central _ nervous _ system , may experience an additive cns depression when <e22> drug2 </e22> are used concomitantly .
effect	antacids : concomitant administration of <e12> drug1 </e12> and <e22> drug2 </e22> may result in increased gastrointestinal toxicity .
effect	<e10> drug1 </e10> inhibits <e20> drug2 </e20> - induced contractions .
effect	<e13> drug1 </e13> can diminish the activity of <e20> drug2 </e20> , procainamide , and succinylcholine .
effect	patients taking <e11> drug1 </e11> concomitantly with either <e22> drug2 </e22> with anticholinergic activity ( eg , antimuscarinics , tricyclic _ antidepressants , and antipsychotics ) or with antihistamines may develop severe adverse effects .
effect	<e10> drug1 </e10> may have additive cns - depressant effects with <e22> drug2 </e22> .
effect	corticosteroids , methylxanthines , and <e10> drug1 </e10> may enhance the hypoglycemic action of oral <e22> drug2 </e22> .
effect	drug1 : <e10> drug1 </e10> may have additive cns - depressive effects when administered with <e22> drug2 </e22> , alcohol , general anesthetics , and other drugs with neuromuscular blocking properties .
effect	when <e10> drug1 </e10> is given concomitantly with oral <e22> drug2 </e22> , it may increase the risk of uterine leiomyomas .
effect	psychoactive _ drugs : hallucinations and psychotic symptoms have been reported when <e10> drug1 </e10> was administered with other <e22> drug2 </e22> .
effect	rarely salicylate toxicity has been reported when <e11> drug1 </e11> was administered concomitantly with salicylates such as <e20> drug2 </e20> .
effect	injection : <e10> drug1 </e10> may reduce the stimulatory effect of <e22> drug2 </e22> , alcohol , barbiturates , sedatives , or other drugs that produce cns depression .
effect	diuretics : studies have shown that <e12> drug1 </e12> can diminish the hypoglycemic action of <e22> drug2 </e22> .
effect	blunting of the antihypertensive effect of <e10> drug1 </e10> may be caused by either direct or indirect actions of <e22> drug2 </e22> on the myocardium .
effect	the concurrent use of other <e12> drug1 </e12> or antihistamine _ drugs with <e21> drug2 </e21> may produce additive or potentiating effects .
effect	the concurrent use of certain antibiotics including <e12> drug1 </e12> with <e22> drug2 </e22> formulations may increase the risk of ototoxicity .
effect	psychoactive _ drugs : hallucinations and paranoia have been reported in patients receiving <e10> drug1 </e10> concomitantly with the use of several psychoactive _ drugs , including alcohol , barbiturates , <e22> drug2 </e22> , general anesthetics , phenothiazines , tranquilizers , and other anesthetics .
effect	thioridazine : coadministration of <e11> drug1 </e11> with <e22> drug2 </e22> ( thiazide _ diuretics ) or other antihypertensive _ drugs has been associated with serious , sometimes fatal , reactions .
effect	this may indicate that <e10> drug1 </e10> and alcohol may enhance the effects of <e22> drug2 </e22> , including alcohol , and should be used with extreme caution in patients taking an anticonvulsant such as valproic _ acid .
effect	skeletal _ muscle _ relaxants : <e10> drug1 </e10> has been reported to reduce the antimuscarinergic effect of <e22> drug2 </e22> , including phenothiazines , barbiturates , and other sympathomimetic _ agents .
effect	the effects of <e10> drug1 </e10> and <e20> drug2 </e20> may be additive .
effect	drug interactions : the cns - depressant properties of <e10> drug1 </e10> may be potentiated by other cns _ depressants , alcohol , barbiturates , <e22> drug2 </e22> , general anesthetics , and antihistamines .
effect	drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , lincomycin , polymyxins , lincomycin , and <e20> drug2 </e20> ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
effect	quinolones , including <e10> drug1 </e10> , and nonsteroidal _ anti - inflammatory _ agents ( nsaids ) may reduce the anticoagulant effects of <e20> drug2 </e20> or its derivatives .
effect	propoxyphene : in a study in healthy volunteers , the administration of <e10> drug1 </e10> to patients receiving either <e22> drug2 </e22> or antihistamines had an additive effect on alpha - blockade .
effect	also , bleeding and / or hypotension has been reported in patients receiving concomitant <e10> drug1 </e10> and <e22> drug2 </e22> .
effect	central _ nervous _ system _ depressants : the concomitant use of <e10> drug1 </e10> and cns _ depressants ( <e22> drug2 </e22> ) has been associated with an increased risk of serious adverse effects .
effect	the <e12> drug1 </e12> may reduce the natriuretic effect of <e20> drug2 </e20> .
effect	furosemide : clinical studies have shown that <e10> drug1 </e10> may reduce the pharmacologic effect of <e20> drug2 </e20> .
effect	<e10> drug1 </e10> may enhance the cytotoxic effects of other <e22> drug2 </e22> , including cisplatin and doxorubicin .
effect	naproxen and other <e12> drug1 </e12> may increase the adverse effects of certain antibiotics , antihistamines , <e22> drug2 </e22> , or other drugs that alter the conduction of the myocardium .
effect	also , bleeding and / or thromboembolism have been reported in patients receiving <e12> drug1 </e12> concomitantly with warfarin or <e22> drug2 </e22> .
effect	<e10> drug1 </e10> has been shown to inhibit the anticoagulant effects of <e22> drug2 </e22> .
effect	with oral <e10> drug1 </e10> and oral <e20> drug2 </e20> used concomitantly , increased duration of macular edema is observed , particularly with longer interval between drugs .
effect	certain drugs including <e10> drug1 </e10> may enhance the effects of <e20> drug2 </e20> .
effect	intrathecal injection of <e10> drug1 </e10> may potentiate the sedative effect of <e20> drug2 </e20> .
effect	the use of other <e12> drug1 </e12> may potentiate the effects of <e20> drug2 </e20> .
effect	ergamisol ( <e10> drug1 </e10> ) injection may potentiate the effect of other <e22> drug2 </e22> , but has no effect on drug1 dose required to produce hypotension .
effect	abased on reports , <e10> drug1 </e10> has been shown to enhance the hypotensive effect of <e22> drug2 </e22> and to potentiate the hypotensive effect of oral anticoagulants , particularly warfarin .
effect	although not studied in humans , systemic administration of <e11> drug1 </e11> may potentiate the effects of certain <e22> drug2 </e22> s , including epinephrine , norepinephrine , and local anesthetics .
effect	only <e13> drug1 </e13> produced potentiation of <e20> drug2 </e20> - induced hyperpolarization in the rat nucleus accumbens , suggesting that the effects of drug1 may be mediated via opioid receptors .
effect	- antidiabetics , <e10> drug1 </e10> may reduce the effects of <e22> drug2 </e22> , diuretics , and corticosteroids .
effect	ketamine : marked additive effects have been reported when <e10> drug1 </e10> is used with <e20> drug2 </e20> .
effect	concomitant administration of <e10> drug1 </e10> with nonsteroidal _ anti - inflammatory _ drugs , <e22> drug2 </e22> , calcium _ channel _ blockers , or other drugs that prolong bleeding time may potentiate bleeding .
effect	the <e12> drug1 </e12> can reduce the antihypertensive effects of <e22> drug2 </e22> .
effect	in diabetic patients , administration of <e10> drug1 </e10> may reduce the antihypertensive effect of <e22> drug2 </e22> .
effect	the hypoglycemic action of <e10> drug1 </e10> may be enhanced by concomitant administration of other drugs that are beta - adrenergic _ blocking _ agents such as <e22> drug2 </e22> and thiazides .
effect	ethanol / nutrition / diet : when <e12> drug1 </e12> are administered concomitantly with <e22> drug2 </e22> , an increased risk of nausea , vomiting , and diarrhea has been reported .
effect	concurrent administration of <e10> drug1 </e10> and <e22> drug2 </e22> ( e , g , , carbamazepine , phenobarbital , primidone , thioxanthene , warfarin , and the phenytoin - sulfate concomitantly ) may produce additive cns depression , resulting in increased risks of seizures , coma , or death .
effect	<e12> drug1 </e12> may enhance the toxicity of <e22> drug2 </e22> , including cyclophosphamide , doxorubicin , cisplatin , doxorubicin and cisapride .
effect	drugs that reduce the effects of <e11> drug1 </e11> may include : certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , and <e22> drug2 </e22> ) ; antihistamines , other neuromuscular _ blocking _ agents , phenothiazines , thioxanthene , and tricyclic _ antidepressants ;
effect	<e10> drug1 </e10> may enhance the cns - depressive action of alcohol , barbiturates , <e22> drug2 </e22> , tranquilizers , or other central _ nervous _ system _ depressants ( including alcohol ) .
effect	<e10> drug1 </e10> may enhance the cns depression associated with <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may potentiate the effects of <e22> drug2 </e22> , such as barbiturates , tranquilizers , or narcotic _ analgesics .
effect	the hypoglycemic action of all <e12> drug1 </e12> may be potentiated by certain drugs , including certain antibiotics , antihistamines , <e22> drug2 </e22> , sulfonamides , monoamine _ oxidase _ inhibitors , and tricyclic _ antidepressants .
effect	drug1 and celexa : <e10> drug1 </e10> may potentiate the effects of <e22> drug2 </e22> .
effect	since <e10> drug1 </e10> can potentiate the activity of <e22> drug2 </e22> , it is advisable to avoid the use of both agents in patients receiving chronic , high - dose oral contraceptives .
effect	<e12> drug1 </e12> can potentiate the effects of <e22> drug2 </e22> , such as diclofenac and retinyl _ acetate .
effect	the benzodiazepines , including <e10> drug1 </e10> , may potentiate the effects of alcohol , <e22> drug2 </e22> , hypnotics , general anesthetics , opioids , sedative - hypnotics , tranquilizers , or other cns _ depressants .
effect	there is thus an increased risk of hypotension and / or hypertension associated with <e10> drug1 </e10> therapy in patients receiving concomitant <e22> drug2 </e22> therapy .
effect	in patients receiving concomitant <e10> drug1 </e10> and <e22> drug2 </e22> , there have been reports of fatal systemic toxicity .
effect	tablets : the benzodiazepines , such as <e10> drug1 </e10> , may reduce the hypoglycemic action of <e20> drug2 </e20> and other drugs that are predominantly glycosylated .
effect	hypersensitivity reactions have been reported in patients taking <e11> drug1 </e11> concomitantly with <e22> drug2 </e22> .
effect	combinations of <e10> drug1 </e10> with other oral <e22> drug2 </e22> , e , g , , warfarin or its derivatives , may increase the risk of bleeding complications .
effect	injection : <e10> drug1 </e10> can reduce the efficacy of <e22> drug2 </e22> sedatives , hypnotics , general anesthetics , phenothiazines , tricyclic _ antidepressants , and other cns _ depressants , when administered with or without concurrent administration of alcohol , general anesthetics , phenothiazines , or other cns _ depressants .
effect	these results suggest that <e10> drug1 </e10> may enhance the antinociceptive effects of <e20> drug2 </e20> .
effect	- drugs whose efficacy is enhanced by <e12> drug1 </e12> include : anticonvulsants , alcohol , <e22> drug2 </e22> , monoamine _ oxidase _ inhibitors , antihistamines , drug2 , corticosteroids , local anesthetics , sedatives , and thiazide _ diuretics .
effect	use with angiotensln _ converting _ enzyme _ inhibitors ( acei ) : patients taking <e10> drug1 </e10> concomitantly with <e20> drug2 </e20> may have a higher risk of developing bradycardia , syncope , and hypotension .
effect	hypersensitivity reactions have been reported when <e11> drug1 </e11> was used concomitantly with certain drugs ( e , g , , <e22> drug2 </e22> , beta _ blockers , antihistamines , monoamine _ oxidase _ inhibitors , local anesthetics , local _ corticosteroid _ parenteral ) .
effect	olanzapine : coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> resulted in higher levels of delirium than did either agent alone .
effect	response to <e12> drug1 </e12> may be impaired when systemic drug1 , including but not limited to chloramphenicol , <e22> drug2 </e22> , and other nonhistamine _ drugs are administered concomitantly .
effect	there have been reports of increased cardiovascular toxicity associated with <e10> drug1 </e10> in patients receiving <e22> drug2 </e22> or diuretics .
effect	- methotrexate ( e , g , , <e10> drug1 </e10> ) combined with <e22> drug2 </e22> ( e , g , , pimozide ) has been associated with a high incidence of central nervous system toxicity .
effect	in patients taking <e12> drug1 </e12> concomitantly with <e22> drug2 </e22> ( e , g , , aminoglycosides , tetracyclines , bacitracin , procainamide , and bromocriptine _ mesylate ) , an increased incidence of gastrointestinal ulceration was noted .
effect	- <e10> drug1 </e10> may potentiate the action of the <e22> drug2 </e22> , methadone , or sedative , hypnotic , tranquilizer , or anesthetics , causing increased cns depressant effects .
effect	higher concentrations of drug1 and <e10> drug1 </e10> were required to inhibit the inhibitory effects of <e20> drug2 </e20> .
effect	ergamisol ( <e10> drug1 </e10> ) has been shown to enhance the anti - inflammatory effect of <e20> drug2 </e20> in experimental models of arthritis and gastric ulcer .
effect	<e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> , but it is not known if these effects are additive .
effect	<e12> drug1 </e12> may interfere with the anticoagulant effect of <e20> drug2 </e20> , in patients receiving anticoagulants concomitantly .
effect	drug interactions : the cns - depressant action of <e11> drug1 </e11> may be potentiated by some narcotic _ analgesic s , alcohol , <e22> drug2 </e22> , barbiturates , general anesthetics , general tranquilizers , general sedatives , general opioids , tricyclic _ antidepressants , and theophylline .
effect	flucytosine : while <e10> drug1 </e10> has been shown to have hypotensive effects , it has been reported to decrease hypotension when coadministered with <e20> drug2 </e20> and other antihypertensive _ drugs .
effect	patients in a dose range of <e10> drug1 </e10> ( 1 - 2 mg / kg ) produced hypotension and hypotensive effects were exacerbated by <e22> drug2 </e22> such as phenothiazines , thioxanthene _ s and noradrenaline .
effect	the administration of <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> , tranquilizers , general anesthetics , tricyclic _ antidepressants , or antihistamines may cause severe respiratory depression , usually resulting in coma or death .
effect	pharmacologic studies indicate that <e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> .
effect	data from a few clinical studies suggest that concomitant use of <e10> drug1 </e10> with <e22> drug2 </e22> may increase the risk of gastrointestinal ulceration .
effect	<e12> drug1 </e12> may reduce the prothrombin time response to <e20> drug2 </e20> by decreasing the effective prothrombin time .
effect	other drugs which may enhance the neuromuscular blocking action of <e10> drug1 </e10> include : theophylline , <e22> drug2 </e22> , tricyclic _ antidepressants , non - selective _ beta - adrenergic _ blocking _ agents , phenothiazines , tranquilizers such as chlordiazepoxide and other benzodiazepines , theophylline , and the action of local anesthetics .
effect	administration of <e10> drug1 </e10> may reduce the clinical effects of <e20> drug2 </e20> .
effect	in patients receiving concomitant <e10> drug1 </e10> therapy , administration of <e22> drug2 </e22> may result in an increase in sympathetic tone .
effect	some <e12> drug1 </e12> may enhance the hypotensive effect of oral <e22> drug2 </e22> , including nifedipine and enalapril .
effect	concomitant treatment with <e10> drug1 </e10> and <e22> drug2 </e22> may potentiate the effects of these drugs .
effect	serious anticholinergic symptoms have been reported in patients receiving <e10> drug1 </e10> concurrently with other anticholinergic _ agents ( e , g , , <e22> drug2 </e22> , antiparkinsonian _ agents , phenothiazines , thioxanthene _ derivatives , etc ) .
effect	when taken orally , <e10> drug1 </e10> may enhance the effects of other drugs that may enhance the activity of <e22> drug2 </e22> , including other antihistamines , other opioids , general anesthetics , and tranquilizers .
effect	the response to <e10> drug1 </e10> may be enhanced by <e20> drug2 </e20> , or certain drugs known to prolong the qtc interval .
effect	some reports have suggested that co - administration of <e12> drug1 </e12> with other oral <e22> drug2 </e22> may result in increased prothrombin times .
effect	it is , however , possible that a concomitant additive cns depressant effect may result if <e10> drug1 </e10> is given with other <e22> drug2 </e22> .
effect	marked symptomatic orthostatic hypotension has been reported after discontinuing <e10> drug1 </e10> in patients receiving <e20> drug2 </e20> .
effect	co - administration : concomitant use of <e11> drug1 </e11> and <e22> drug2 </e22> can result in additive cns depression .
effect	pharmacodynamic interactions : the anticoagulant effects of <e12> drug1 </e12> may be potentiated by certain <e22> drug2 </e22> .
effect	<e12> drug1 </e12> may enhance the cns depressant effects of narcotic _ analgesics , phenothiazines , barbiturates , general anesthetics , tranquilizers , <e22> drug2 </e22> , and other cns _ depressants .
effect	the hypoglycemic action of <e10> drug1 </e10> may be potentiated by certain drugs including <e22> drug2 </e22> and salicylates .
effect	concomitant treatment with <e10> drug1 </e10> and <e22> drug2 </e22> can result in increased anticholinergic effects and adverse effects .
effect	<e10> drug1 </e10> and morphine reduce the cardiac effects of <e20> drug2 </e20> and epinephrine , respectively .
effect	when taken orally , <e12> drug1 </e12> may potentiate the effect of other oral <e22> drug2 </e22> .
effect	most of the agents that are reported to produce hypotension when administered with <e10> drug1 </e10> are <e22> drug2 </e22> and it is unknown if similar hypotensive effects result from their combined action with other drug2 .
effect	<e12> drug1 </e12> and <e22> drug2 </e22> ( eg , epinephrine and norepinephrine ) have additive depressant effects .
effect	additive cns depression , including hypotension , bradycardia , and loss of consciousness , has been observed when <e10> drug1 </e10> was administered concurrently with alcohol , <e20> drug2 </e20> , thioridazine , and alcohol .
effect	pharmacodynamic interactions : the cns effects of <e10> drug1 </e10> may be potentiated by alcohol , <e22> drug2 </e22> , barbiturates , general anesthetics , monoamine _ oxidase _ inhibitors , general anesthetics , and quinidine .
effect	aminoglycosides : the concomitant use of <e10> drug1 </e10> with drug1 , <e20> drug2 </e20> , gentamicin , or netilmicin has been associated with a small number of cases of serious infection ( 1 % - 3 % of patients ) .
effect	edema has been reported when <e10> drug1 </e10> was used concomitantly with <e20> drug2 </e20> .
effect	there are case reports suggesting that <e10> drug1 </e10> may decrease the efficacy of <e22> drug2 </e22> .
effect	combined treatment with <e10> drug1 </e10> and <e20> drug2 </e20> produced additive effects on blood glucose and c - peptide levels in diabetic patients , although blood glucose levels were maintained .
effect	coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> decreased the anticoagulant effect of drug2 .
effect	it was concluded that <e12> drug1 </e12> may inhibit the activity of <e22> drug2 </e22> .
effect	prolonged recovery time may occur in patients taking the <e12> drug1 </e12> concomitantly with <e22> drug2 </e22> .
effect	drug1 : clinical studies in humans have shown that <e10> drug1 </e10> may enhance the effects of <e22> drug2 </e22> and thiazide _ diuretics .
effect	this appears to be the first report of a fatal , hypotensive , myocardial infarction associated with the concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> .
effect	additive cns depression has been reported following coadministration of <e11> drug1 </e11> and <e20> drug2 </e20> .
effect	the concurrent use of <e10> drug1 </e10> with other <e22> drug2 </e22> may enhance the hypomanic effects of these agents .
effect	concomitant use of <e10> drug1 </e10> with other <e22> drug2 </e22> may result in increased prothrombin activity and increased risk of bleeding complications .
effect	concurrent use of <e10> drug1 </e10> and <e22> drug2 </e22> has been shown to result in an additive effect .
effect	anesthetics / sedatives : agents used by the anesthetics / sedatives division of the us food and drug administration to aid in the anesthesia and sedation division ' s ability to control the bleeding effect of drugs ( b drug2 ) : may cause some patients to require larger doses of the <e12> drug1 </e12> to achieve the desired hypotensive effect when coadministered with <e21> drug2 </e21> .
effect	<e12> drug1 </e12> may enhance the effects of <e20> drug2 </e20> , barbiturates , tranquilizers such as chlordiazepoxide , or other cns _ depressants , causing increased cns depression .
effect	<e11> drug1 </e11> may have additive cns depressant effects with alcohol and other cns _ depressants , such as <e22> drug2 </e22> and opiates .
effect	<e10> drug1 </e10> has additive anticoagulant effects when coadministered with <e20> drug2 </e20> .
effect	pharmacodynamic interactions : the cns _ depressant effects of <e10> drug1 </e10> may be additive with other cns _ depressants , including alcohol , barbiturates , <e22> drug2 </e22> , and antihistamines .
effect	<e10> drug1 </e10> attenuates the natriuretic response to <e20> drug2 </e20> in pigs .
effect	an encephalopathic syndrome , characterized by myoclonic seizures , coma , and loss of consciousness has been observed in patients receiving <e11> drug1 </e11> concomitantly with the anti - epileptic drugs carbamazepine , drug2 , drug2 _ hydrochloride and <e20> drug2 </e20> .
effect	certain drugs including beta - blockers , <e10> drug1 </e10> , sulfonamides , quinine , monoamine _ oxidase _ inhibitors , and the antihistamines chlordiazepoxide and naratriptan may potentiate the neuromuscular blocking action of <e22> drug2 </e22> .
effect	the adverse effects of <e12> drug1 </e12> , including respiratory depression , prolonging of the qt interval , and cns depression , may be potentiated by <e22> drug2 </e22> .
effect	<e10> drug1 </e10> may enhance the effects of other <e22> drug2 </e22> and other cns _ depressants .
effect	interactions with other cns agents : concurrent administration of <e11> drug1 </e11> and other cns _ depressants ( e , g , , alcohol , barbiturates , general anesthetics , tranquilizers , or <e22> drug2 </e22> ) may result in additive cns depressant effects .
effect	nephrotoxicity has been reported with concomitant use of <e11> drug1 </e11> and other oral <e22> drug2 </e22> .
effect	furosemide : clinical studies suggest that <e10> drug1 </e10> may enhance the neuromuscular blocking action of <e20> drug2 </e20> .
effect	agents causing renin release : <e10> drug1 </e10> potentiates the antihypertensive effects of <e22> drug2 </e22> and agents which are catecholamine - depleting .
effect	interactions with other cns agents : concurrent administration of <e11> drug1 </e11> and other cns _ depressants such as alcohol , barbiturates , <e22> drug2 </e22> , or antihistamines may produce serious , sometimes fatal , symptoms .
effect	<e10> drug1 </e10> may reduce the antihypertensive effect of <e20> drug2 </e20> .
effect	only <e13> drug1 </e13> may potentiate the antinociceptive effects of <e20> drug2 </e20> and other opiates .
effect	the hypoglycemic action of <e11> drug1 </e11> may be additive with those of drugs such as <e22> drug2 </e22> and local anesthetics , sulfonamides , phenothiazines , and theophylline .
effect	ace - inhibitors : reports suggest that <e10> drug1 </e10> may enhance the cardiac effects of <e22> drug2 </e22> , such as norepinephrine , and therefore , the concomitant use of drug1 with a beta - blocker is not recommended .
effect	the anticoagulant effect of <e10> drug1 </e10> may be potentiated by <e22> drug2 </e22> or other inhibitors of platelet aggregation , inhibitors of platelet - endothelial interactions , or anticoagulants such as warfarin or its derivatives .
effect	the concurrent use of <e10> drug1 </e10> with <e20> drug2 </e20> or any other nsaid may increase the risk of gastrointestinal ulceration or other gastrointestinal toxicity .
effect	drug1 : <e12> drug1 </e12> may potentiate the neuromuscular blocking action of <e20> drug2 </e20> or other opioids .
effect	in one controlled study , the addition of intravenous <e10> drug1 </e10> to intravenous <e22> drug2 </e22> resulted in increases in blood pressure in patients with hypertension but had no effect on potassium levels .
effect	immediate and extended release tablets - the potential for serious cardiac arrhythmias has been increased by the concomitant use of <e11> drug1 </e11> tablets with <e20> drug2 </e20> and / or diuretics .
effect	however , the systemic effects of <e10> drug1 </e10> may be potentiated by alcohol , <e22> drug2 </e22> and other drugs that may enhance cns depression .
effect	these results suggest that <e10> drug1 </e10> may have additive effects with those of <e22> drug2 </e22> on the progression of atopic dermatitis .
effect	other drugs which may enhance the neuromuscular blocking action of <e10> drug1 </e10> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e20> drug2 </e20> , colistin , drug2 , drug2 sodium , and sodium _ colistimethate ) , magnesium salts , local anesthetics , procainamide , and quinidine .
effect	drug1 : <e10> drug1 </e10> has been reported to potentiate the effects of <e22> drug2 </e22> , including alcohol .
effect	<e10> drug1 </e10> and / or acetaminophen may potentiate the effects of <e22> drug2 </e22> , tricyclic _ antidepressants , and other psychotropics , resulting in increased cns toxicity .
effect	the cns effects of <e10> drug1 </e10> can be potentiated by alcohol , other cns _ depressants , barbiturates , <e22> drug2 </e22> , general anesthetics , mao _ inhibitors , and other drugs that are extensively metabolized by this isozyme .
effect	additive cns depression may be induced by concomitant administration of <e10> drug1 </e10> and <e22> drug2 </e22> .
effect	there are rare reports in the literature of hypoglycemic action associated with the concomitant use of <e10> drug1 </e10> and the anticoagulant <e22> drug2 </e22> , including warfarin and its derivatives .
effect	synergism was observed when <e10> drug1 </e10> and <e20> drug2 </e20> were used in combination .
effect	tricyclic _ antidepressants : use of <e10> drug1 </e10> with tricyclic _ antidepressants ( tricyclic _ antidepressants , <e22> drug2 </e22> ) may result in additive cns depression .
effect	the administration of <e10> drug1 </e10> can enhance the effects of <e20> drug2 </e20> .
effect	selective _ serotonin _ reuptake _ inhibitors ( <e12> drug1 </e12> ) may enhance the effects of other psychotropic _ agents , including alcohol , <e22> drug2 </e22> , tranquilizers , or other cns _ depressants .
effect	the concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> may result in increased toxicity .
effect	other drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , and clindamycin ) , magnesium salts , <e22> drug2 </e22> , local anesthetics , and quinidine .
effect	central _ nervous _ system _ depressants : the concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> can produce severe hypotension .
effect	immediate and extended release tablets - in some patients , <e12> drug1 </e12> may enhance the neuromuscular blocking action of <e20> drug2 </e20> or indomethacin .
effect	selective _ serotonin _ reuptake _ inhibitors ( ssris ) such as <e10> drug1 </e10> may enhance the psychotropic effects of <e22> drug2 </e22> , including other antidepressants , barbiturates , sedatives , general anesthetics , tranquilizers , and other cns _ depressants .
effect	butalbital , <e10> drug1 </e10> , and alcohol potentiate the cns - depressive action of <e22> drug2 </e22> , including nortriptyline .
effect	- non - steroidal _ anti - inflammatory _ drugs : agents such as non - steroidal _ anti - inflammatory _ drugs ( drug1 ) and other <e12> drug1 </e12> may have an additive effect on <e22> drug2 </e22> blocking .
effect	( <e12> drug1 </e12> have additive depressant effects with <e22> drug2 </e22> and may be associated with cns depression .
effect	<e10> drug1 </e10> may enhance the effect of other <e22> drug2 </e22> .
effect	catecholamine - depleting agents : patients on <e12> drug1 </e12> therapy may experience an increase in heart rate and blood pressure when <e20> drug2 </e20> is administered concomitantly with such agents .
effect	serious cardiac dysrhythmias , notably syncope , have been reported with concomitant use of <e11> drug1 </e11> and <e20> drug2 </e20> .
effect	drug1 - prior to concomitant administration of <e10> drug1 </e10> with other drugs including antidepressants , <e22> drug2 </e22> , antianxiety _ agents , monoamine _ oxidase _ inhibitors ( maois ) and tricyclic _ antidepressants ( tcas ) , the possibility of an additive cns depressant effect may have been increased .
effect	<e10> drug1 </e10> also potentiates the effects of <e22> drug2 </e22> , barbiturates , tricyclic _ antidepressants and other sympathomimetics .
effect	beta - blockers , <e10> drug1 </e10> and reserpine may enhance the effects of <e22> drug2 </e22> , and it is not known if the effects of drug2 are enhanced by reserpine .
effect	the action of <e10> drug1 </e10> on [ ca ( 2 + ) ] i was impaired in the presence of <e22> drug2 </e22> , which suggests that drug1 may potentiate the hypotensive effect of [ ca ( 2 + ) ] i _ depletors .
effect	serious toxicity may result when <e12> drug1 </e12> are administered concomitantly with <e22> drug2 </e22> .
effect	lethargy and somnolence have been reported following the concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> .
effect	in patients receiving <e12> drug1 </e12> and <e22> drug2 </e22> concomitantly , the risk of hypotension , bradycardia , and orthostatic hypotension may be increased .
effect	phenobarbital toxicity has been reported following concomitant administration of <e11> drug1 </e11> and <e20> drug2 </e20> .
effect	<e10> drug1 </e10> may potentiate the effects of other psychoactive _ drugs , <e22> drug2 </e22> , general anesthetics , tranquilizers , barbiturates , opioids , general anesthetics , or other cns _ depressants , resulting in an increased cns depression .
effect	additive adverse effects have been reported with the combination of <e10> drug1 </e10> with alcohol , nonsteroidal _ anti - inflammatory _ agents , <e22> drug2 </e22> and other drugs known to interact with alcohol .
effect	the administration of <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> , antihistamines , and alcohol can result in significant increases in blood pressure and serum triglyceride levels .
effect	selective _ serotonin _ reuptake _ inhibitors ( <e12> drug1 </e12> ) may decrease the efficacy of <e20> drug2 </e20> .
effect	these results suggest that concomitant administration of <e12> drug1 </e12> and <e22> drug2 </e22> may lead to increased adverse effects .
effect	<e12> drug1 </e12> have been reported to reduce the activity of some oral anticoagulants such as <e20> drug2 </e20> and its derivatives .
effect	tricyclic _ antidepressants : use of <e10> drug1 </e10> with <e22> drug2 </e22> may increase the risk of depression and other serious psychiatric disorders .
effect	agents increasing serum potassium : the concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> ( na - ptc ) is likely to increase the serum potassium level , and the resulting hypokalemia should be avoided .
effect	coadministration of <e10> drug1 </e10> and <e22> drug2 </e22> may potentiate adverse effects .
effect	<e10> drug1 </e10> may also reduce the hypotensive effects of <e22> drug2 </e22> therapy .
effect	<e10> drug1 </e10> may increase the effect of <e22> drug2 </e22> , adrenocorticotropin or other glucocorticoids .
effect	the administration of <e12> drug1 </e12> to patients receiving coumarin - type anticoagulants such as <e22> drug2 </e22> may result in increased prothrombin time .
effect	in monkeys , the <e12> drug1 </e12> may have an additive effect when given with <e21> drug2 </e21> .
effect	interactions with other cns agents : concurrent use of <e10> drug1 </e10> and an <e22> drug2 </e22> ( e , g , , an opioid , an antidepressant , an antihistamine , an alcohol , or a tranquilizer ) may result in additive central nervous system depressant effects .
effect	beta - blockers , clonidine and <e10> drug1 </e10> may enhance the effects of <e21> drug2 </e21> .
effect	uricosuric _ agents : <e11> drug1 </e11> may reduce the antihypertensive effect of <e20> drug2 </e20> , propranolol , and other agents which are vasoconstrictive and have been shown to reduce the antihypertensive effect of aldosterone .
effect	other drugs which may enhance the neuromuscular blocking action of <e11> drug1 </e11> include certain antibiotics ( e , g , , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium _ colistimethate , and sodium _ citrate ) , magnesium salts , <e22> drug2 </e22> , procainamide , and quinidine .
effect	in diabetic patients , administration of <e10> drug1 </e10> may reduce the hypoglycemic action of <e22> drug2 </e22> .
effect	reports suggest that <e12> drug1 </e12> have a negative effect on platelet function in patients undergoing <e22> drug2 </e22> therapy .
effect	<e10> drug1 </e10> can decrease the blood glucose - lowering effect of <e22> drug2 </e22> , such as the oral agents metformin , insulin , and glimepiride .
effect	in these patients , concomitant administration of <e10> drug1 </e10> with <e22> drug2 </e22> s and antihypertensive _ agents , e , g , , diuretics , may be beneficial .
effect	the administration of theophylline , <e10> drug1 </e10> or their salts to patients receiving <e22> drug2 </e22> may cause hepatic impairment and may increase the risk of hepatotoxicity .
effect	patients receiving high doses of the <e12> drug1 </e12> and <e20> drug2 </e20> may exhibit hypoglycemia , and drug2 may have an additive effect with other drugs such as coumarins , diuretics , or thyroid _ products .
effect	antihypertensives : <e12> drug1 </e12> may reduce the hypoglycemic effect of <e20> drug2 </e20> , amiloride and thiazide _ diuretics .
effect	when <e10> drug1 </e10> is coadministered with other <e22> drug2 </e22> , the potential effects of enhanced central nervous system effects may be greater .
effect	due to their wide range of pharmacological actions , <e10> drug1 </e10> may also potentiate the effects of other narcotic _ analgesic s , alcohol , general anesthetics , tranquilizers such as <e22> drug2 </e22> , or other cns _ depressants , including barbiturates and other central _ nervous _ system _ depressants .
effect	- drugs whose hypoglycemic action may be enhanced by <e10> drug1 </e10> include : beta _ adrenergic _ blocking _ agents , corticosteroids , sulfonylureas , monoamine _ oxidase _ inhibitors , <e22> drug2 </e22> , and certain antihistamines .
effect	norepinephrine : <e12> drug1 </e12> can enhance the adrenergic effects of <e22> drug2 </e22> .
effect	immediate and extended release <e12> drug1 </e12> tablets can cause mild to severe withdrawal reactions when given concomitantly with strong opioids , <e22> drug2 </e22> or other sedatives .
effect	thiazide _ diuretics : the concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> has been associated with increased renal injury .
effect	severe hypoglycemia has been reported in patients treated with low doses of <e12> drug1 </e12> and in patients receiving concomitant <e22> drug2 </e22> .
effect	concomitant use of other narcotic _ analgesic s , <e12> drug1 </e12> , general anesthetics , tranquilizers , sedative - hypnotics , tricyclic _ antidepressants , or other cns _ depressants ( including alcohol ) may potentiate the cns depression caused by <e21> drug2 </e21> .
effect	the hypoglycemic action of <e10> drug1 </e10> may be augmented by other <e22> drug2 </e22> and theophylline .
effect	the benzodiazepines , including <e10> drug1 </e10> and chlordiazepoxide , have additive depressant effects on anesthesiologists and patients sedated with <e22> drug2 </e22> .
effect	administration of <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> , in addition to any other antineoplastic therapy , may result in an increased risk of development of corticosteroid - induced anemia .
effect	<e10> drug1 </e10> can prolong the action of other <e22> drug2 </e22> drugs , such as clonidine , propranolol , and salicylates .
effect	there have been reports of hepatic toxicity associated with the concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> , including those involving the cytochrome p - 450 isoenzyme .
effect	suppression by <e10> drug1 </e10> or azide may be responsible for the antihypertensive effect of <e21> drug2 </e21> .
effect	pharmacodynamic interactions : the cns _ depressant effects of <e11> drug1 </e11> may be additive with alcohol , <e22> drug2 </e22> , general anesthetics , hypnotics , and other central _ nervous _ system _ depressants .
effect	<e11> drug1 </e11> may enhance the effect of <e20> drug2 </e20> , corticosteroids , anticoagulants , and other drugs that are highly toxic to the nervous system .
effect	<e11> drug1 </e11> may enhance the hypotensive effects of <e20> drug2 </e20> and other drugs that enhance cardiovascular reflexes .
